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A B S T R A C T
Background
Delirium is a syndrome characterised by an acute disturbance of attention and awareness which develops over a short time period and
fluctuates in severity over the course of the day. It is commonly experienced during inpatient admission in the terminal phase of illness. It
can cause symptoms such as agitation and hallucinations and is distressing for terminally ill people, their families and staE. Delirium may
arise from any number of causes and treatment should aim to address these causes. When this is not possible, or treatment is unsuccessful,
drug therapy to manage the symptoms may become necessary.
This is the second update of the review first published in 2004.
Objectives
To evaluate the eEectiveness and safety of drug therapies to manage delirium symptoms in terminally ill adults.
Search methods
We searched CENTRAL, MEDLINE, Embase, CINAHL and PsycINFO from inception to July 2019, reference lists of retrieved papers, and online
trial registries.
Selection criteria
We included randomised controlled trials of drug therapies in any dose by any route, compared to another drug therapy, a non-
pharmacological approach, placebo, standard care or wait-list control, for the management of delirium symptoms in terminally ill adults
(18 years or older).
Data collection and analysis
We independently screened citations, extracted data and assessed risk of bias. Primary outcomes were delirium symptoms; agitation score;
adverse events. Secondary outcomes were: use of rescue medication; cognitive status; survival. We applied the GRADE approach to assess
the overall quality of the evidence for each outcome and we include eight 'Summary of findings' tables.
Main results
We included four studies (three new to this update), with 399 participants. Most participants had advanced cancer or advanced AIDS,
and mild- to moderate-severity delirium. Meta-analysis was not possible because no two studies examined the same comparison. Each
study was at high risk of bias for at least one criterion. Most evidence was low to very low quality, downgraded due to very serious study
Drug therapy for delirium in terminally ill adults (Review)
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limitations, imprecision or because there were so few data. Most studies reported delirium symptoms; two reported agitation scores; three
reported adverse events with data on extrapyramidal eEects; and none reported serious adverse events.
1. Haloperidol versus placebo
There may be little to no diEerence between placebo and haloperidol in delirium symptoms within 24 hours (mean diEerence (MD) 0.34,
95% confidence interval (CI) −0.07 to 0.75; 133 participants). Haloperidol may slightly worsen delirium symptoms compared with placebo
at 48 hours (MD 0.49, 95% CI 0.10 to 0.88; 123 participants with mild- to moderate-severity delirium).
Haloperidol may reduce agitation slightly compared with placebo between 24 and 48 hours (MD −0.14, 95% −0.28 to −0.00; 123 participants
with mild- to moderate-severity delirium).
Haloperidol probably increases extrapyramidal adverse eEects compared with placebo (MD 0.79, 95% CI 0.17 to 1.41; 123 participants with
mild- to moderate-severity delirium).
2. Haloperidol versus risperidone
There may be little to no diEerence in delirium symptoms with haloperidol compared with risperidone within 24 hours (MD −0.42, 95%
CI −0.90 to 0.06; 126 participants) or 48 hours (MD −0.36, 95% CI −0.92 to 0.20; 106 participants with mild- to moderate-severity delirium).
Agitation scores and adverse events were not reported for this comparison.
3. Haloperidol versus olanzapine
We are uncertain whether haloperidol reduces delirium symptoms compared with olanzapine within 24 hours (MD 2.36, 95% CI −0.75 to
5.47; 28 participants) or 48 hours (MD 1.90, 95% CI −1.50 to 5.30, 24 participants). Agitation scores and adverse events were not reported
for this comparison.
4. Risperidone versus placebo
Risperidone may slightly worsen delirium symptoms compared with placebo within 24 hours (MD 0.76, 95% CI 0.30 to 1.22; 129
participants); and at 48 hours (MD 0.85, 95% CI 0.32 to 1.38; 111 participants with mild- to moderate-severity delirium).
There may be little to no diEerence in agitation with risperidone compared with placebo between 24 and 48 hours (MD −0.05, 95% CI −0.19
to 0.09; 111 participants with mild- to moderate-severity delirium).
Risperidone may increase extrapyramidal adverse eEects compared with placebo (MD 0.73 95% CI 0.09 to 1.37; 111 participants with mild-
to moderate-severity delirium).
5. Lorazepam plus haloperidol versus placebo plus haloperidol
We are uncertain whether lorazepam plus haloperidol compared with placebo plus haloperidol improves delirium symptoms within 24
hours (MD 2.10, 95% CI −1.00 to 5.20; 50 participants with moderate to severe delirium), reduces agitation within 24 hours (MD 1.90, 95% CI
0.90 to 2.80; 52 participants), or increases adverse events (RR 0.70, 95% CI −0.19 to 2.63; 31 participants with moderate to severe delirium).
6. Haloperidol versus chlorpromazine
We are uncertain whether haloperidol reduces delirium symptoms compared with chlorpromazine at 48 hours (MD 0.37, 95% CI −4.58 to
5.32; 24 participants). Agitation scores were not reported. We are uncertain whether haloperidol increases adverse events compared with
chlorpromazine (MD 0.46, 95% CI −4.22 to 5.14; 24 participants).
7. Haloperidol versus lorazepam
We are uncertain whether haloperidol reduces delirium symptoms compared with lorazepam at 48 hours (MD −4.88, 95% CI −9.70 to
0.06; 17 participants). Agitation scores were not reported. We are uncertain whether haloperidol increases adverse events compared with
lorazepam (MD −6.66, 95% CI −14.85 to 1.53; 17 participants).
8. Lorazepam versus chlorpromazine
We are uncertain whether lorazepam reduces delirium symptoms compared with chlorpromazine at 48 hours (MD 5.25, 95% CI 0.38 to
10.12; 19 participants), or increases adverse events (MD 7.12, 95% CI 1.08 to 15.32; 18 participants). Agitation scores were not reported.
Secondary outcomes: use of rescue medication, cognitive impairment, survival
There were insuEicient data to draw conclusions or assess GRADE.
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Authors' conclusions
We found no high-quality evidence to support or refute the use of drug therapy for delirium symptoms in terminally ill adults. We found
low-quality evidence that risperidone or haloperidol may slightly worsen delirium symptoms of mild to moderate severity for terminally
ill people compared with placebo. We found moderate- to low-quality evidence that haloperidol and risperidone may slightly increase
extrapyramidal adverse events for people with mild- to moderate-severity delirium. Given the small number of studies and participants
on which current evidence is based, further research is essential.
P L A I N   L A N G U A G E   S U M M A R Y
Drug therapy for delirium in terminally ill adults
Background
Delirium is common in people with a terminal illness. A person experiencing delirium may be confused, lack concentration, have disturbed
patterns of sleep and waking, and experience hallucinations. Delirium can start suddenly and can cause distress to both the person and
their family. Delirium may be caused by the underlying disease with which the person is aEected, or as a side eEect of drugs or other
symptoms. ONen it is not clear why a person has delirium. The multifaceted nature of delirium makes its management challenging. When
it is not possible to identify the underlying cause, drug treatments are sometimes used to manage the symptoms.
Study characteristics
The aim of this review was to find out what we know about the eEectiveness and side eEects of drugs in the management of delirium in
adults with a terminal illness. For the purpose of this review, terminally ill adults includes anyone with an advanced progressive illness
such as advanced cancer, advanced dementia or organ failure, as well as those receiving hospice and end-of-life care. We compared drug
therapy with placebo (a substance with no known active eEect), usual care, or any other drug or non-drug treatment.
Key results
Our search to July 2019 found four trials, involving 399 adults in total. Participants had advanced cancer (three studies) or advanced AIDS
(one study), and all had symptoms of delirium. The drugs evaluated were antipsychotics (three studies) or benzodiazepines (one study),
compared to placebo or each other, on their own or in combination with another drug or placebo.
Most studies reported the outcomes we deemed most important: delirium symptoms, agitation, and adverse events (side eEects).
It was not possible to combine the data from diEerent studies due to a lack of similarity between them. We found low-quality evidence
that certain drugs (haloperidol and risperidone) may slightly worsen delirium symptoms for terminally ill adults with mild- to moderate-
severity delirium. We found moderate-quality evidence that haloperidol probably slightly increases adverse side eEects for people with
mild- to moderate-severity delirium.
Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low quality evidence means
that we are very uncertain about the results. High-quality evidence means that we are very confident in the results. We found no high-
quality evidence. This was due to the small number of people taking part, the number of people dropping out of the studies, and the small
number of studies.
Conclusion
We found low-quality evidence that, compared to placebo, drug therapy (specifically haloperidol and risperidone) may slightly worsen
delirium symptoms in terminally ill people with delirium of mild to moderate severity. We found low- to moderate-quality evidence that
these drugs may slightly increase adverse side eEects. Given the small numbers of studies and participants on which current evidence is
based, further research is essential.
Drug therapy for delirium in terminally ill adults (Review)





































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Summary of findings: haloperidol compared with placebo for delirium in terminally ill adults
Haloperidol compared with placebo for delirium in terminally ill adults
Patient or population: terminally ill adults with delirium
Settings: inpatient hospice or palliative care service
Intervention: haloperidol
Comparison: placebo
Illustrative comparative risks* (95% CI)
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Mean extrapyramidal effects in the haloperidol group was
0.79 higher







*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence































































































































Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a Measured using 3 of the 5 items from the Nursing Delirium Screening Scale. Items were: inappropriate behavior, inappropriate communication and illusions and hallucinations
(severity range: 0 to 6; higher score means worse delirium).
bDowngraded by 2 levels due to very serious study limitations because of unclear risk of bias due to sample size and use of an unvalidated outcome measure.
c Measured using the Richmond Agitation and Sedation Scale (10 point scale; +4 combative, 0 alert and calm, −5 unarousable). Lower scores reflect less agitation/greater sedation.
d Downgraded by 2 levels due to very serious study limitations because of unclear risk of bias due to sample size and imprecision as the confidence interval for the mean diEerence
has an upper limit of 0, so there may or may not be an eEect depending on where the true point estimate lies.
e Measured using the Extrapyramidal Symptoms Rating Scale. The scale identifies 4 drug-induced movement disorders: parkinsonism, akathisia, dystonia and tardive dyskinesia.
f Downgraded by 1 level due to serious study limitations because of unclear risk of bias due to sample size.
 
 
Summary of findings 2.   Summary of findings: haloperidol compared with risperidone for delirium in terminally ill adults
Haloperidol compared with risperidone for delirium in terminally ill adults
Patient or population: terminally ill adults with delirium
Settings: inpatient hospice or palliative care service
Intervention: haloperidol
Comparison: risperidone
Illustrative comparative risks* (95% CI)












Symptoms of delirium within 24 hoursa Mean delirium was
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Mean delirium was 0.42
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Agitation between 24 and 48 hours - - - - - Outcome not
reported
Adverse events including extrapyramidal ef-
fects
- - - - - Outcome not
reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a Measured using 3 of the 5 items from the Nursing Delirium Screening Scale. Items were: inappropriate behaviour, inappropriate communication and illusions and hallucinations
(severity range: 0 to 6; higher score means worse delirium).
b Downgraded by 2 levels because of very serious study limitations due to high risk of bias due to attrition and sample size, and increased risk of potential bias and random eEects
as the evidence is based on a single study.
 
 
Summary of findings 3.   Summary of findings: haloperidol compared with olanzapine for delirium in terminally ill adults
Haloperidol compared with olanzapine for delirium in terminally ill adults
Patient or population: terminally ill adults with delirium
Settings: hospital palliative care centre
Intervention: haloperidol
Comparison: olanzapine
Illustrative comparative risks* (95% CI)


































































































































































Agitation within 24 hours - - - - - Outcome not
measured
Agitation between 24 and 48 hours - - - - - Outcome not
measured
Adverse events including extrapyramidal
effects
- - - - - Outcome not
measured
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aMeasured using the Delirium Rating Scale (severity range: 0 to 46; higher score means worse delirium).
bDowngraded by 3 levels because there were so few data that the results were highly susceptible to the random play of chance.
 
 
Summary of findings 4.   Summary of findings: risperidone compared with placebo for delirium in terminally ill adults
Risperidone compared with placebo for delirium in terminally ill adults
Patient or population: terminally ill adults with delirium

































































































































Illustrative comparative risks* (95% CI)














Mean delirium was 0.96 Mean delirium was
0.76 higher








um between 24 and 48
hoursa
Mean delirium was 0.70 Mean delirium was
0.85higher























Mean extrapyramidal effects in the risperidone group was
0.73higher







*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a Measured using 3 of the 5 items from the Nursing Delirium Screening Scale. Items were: inappropriate behavior, inappropriate communication and illusions and hallucinations
(severity range: 0 to 6; higher score means worse delirium).
bDowngraded by 2 levels because of very serious study limitations due to high risk of bias due to attrition and sample size, and increased risk of potential bias and random eEects
as the evidence is based on a single study.
cMeasured using the Richmond Agitation Scale (10 point scale; +4 combative, 0 alert and calm, −5 unarousable). Lower scores reflect less agitation/greater sedation.

































































































































Summary of findings 5.   Summary of findings: lorazepam plus haloperidol compared with placebo plus haloperidol for delirium in terminally ill
adults
Lorazepam plus haloperidol compared with placebo plus haloperidol for delirium in terminally ill adults
Patient or population: terminally ill adults with severe delirium
Settings: acute palliative care unit
Intervention: lorazepam plus haloperidol
Comparison: placebo plus haloperidol
Illustrative comparative risks* (95% CI)

















Mean change in deliri-
um was 0.4
Mean change in delirium
was 2.1 higher







Higher scores = lower deliri-
um.
Symptoms of delirium be-
tween 24 and 48 hours
- - - - - Outcome not measured
Agitation within 24 hoursc Mean reduction in agi-
tation was 2.3
Mean reduction in agita-
tion was 1.9 higher.







Higher scores = less agitation
or greater sedation
Agitation between 24 and
48 hoursc
- - - - - Outcome not measured
Adverse events including
extrapyramidal effectsd







*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio.
































































































































High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a Measured using the Memorial Delirium Assessment Scale (range severity: 0 to 30; higher score means worse delirium).
b Downgraded by 3 levels because there were so few data that the results were highly susceptible to the random play of chance.
c Measured using the Richmond Agitation-Sedation Scale (10 point scale; +4 combative, 0 alert and calm, −5 unarousable). Lower scores reflect less agitation/greater sedation.
d Measured by the UKU adverse eEects rating scale. 8 neurologic symptoms were documented using the UKU adverse eEects rating scale at baseline and day 3 (dystonia, rigidity,
hypokinesia or akinesia, hyperkinesia, tremor, akathisia, epileptic seizures, paraesthesias). Each item was assigned a score from 0 (absent) to 3 (most severe) based on symptom
severity of the last 3 days. Reported in the table are the most common reported events; hypokinesia or akinesia.
 
 
Summary of findings 6.   Summary of findings: haloperidol compared with chlorpromazine for delirium in terminally ill adults
Haloperidol compared with chlorpromazine for delirium in terminally ill adults




Illustrative comparative risks* (95% CI)












Symptoms of delirium within 24 hours - - - - - Outcome not
measured














































































































































Agitation between 24 and 48 hours - - - - - Outcome not
measured





fects was 0.46 higher







*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a Measured using the Delirium Rating Scale (severity range: 0 to 46; higher score means worse delirium).
b Downgraded by 3 levels because there were so few data that the results were highly susceptible to the random play of chance.




Summary of findings 7.   Summary of findings: haloperidol compared with lorazepam for delirium in terminally ill adults
Haloperidol compared with lorazepam for delirium in terminally ill adults




Illustrative comparative risks* (95% CI)
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- - - - - Outcome not
measured
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24 and 48 hoursa








Agitation within 24 hours - - - - - Outcome not
measured
Agitation between 24 and 48
hours
- - - - - Outcome not
measured
Adverse events including ex-
trapyramidal effectsc
All 6 participants developed
treatment limiting adverse
events including over seda-
tion, disinhibition, ataxia and
increased confusion. Use of




"No clinically significant med-
ication-related [adverse events]
were noted"










*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aMeasured by the Delirium Rating Scale (severity range: 0 to 46; higher score means worse delirium).
bDowngraded by 3 levels because there were so few data that the results were highly susceptible to the random play of chance. Only 6 participants were recruited to the lorazepam
arm and the results were susceptible to overestimating or underestimating the treatment eEect.



































































































































Summary of findings 8.   Summary of findings: lorazepam compared with chlorpromazine for delirium in terminally ill adults
Lorazepam compared with chlorpromazine for delirium in terminally ill adults




Illustrative comparative risks* (95% CI)













Symptoms of delirium within 24
hours
- - - - - Outcome not
measured
Symptoms of delirium between
24 and 48 hoursa








Agitation within 24 hours - - - - - Outcome not
measured
Agitation between 24 and 48
hours
- - - - - Outcome not
measured







All 6 participants developed
treatment-limiting adverse
events including over seda-
tion, disinhibition, ataxia and
increased confusion. Use of lo-
razepam was halted due to ad-
verse event










*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
































































































































CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
a Measured by the Delirium Rating Scale (severity range: 0 to 46; higher score means worse delirium).
b Downgraded by 3 levels because there were so few data that the results were highly susceptible to the random play of chance.
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B A C K G R O U N D
This is the second update of a review originally published on drug
therapy for delirium in terminally ill adults (Jackson 2004); and
previously updated in 2012 (Candy 2012).
Description of the condition
Delirium is a complex neuropsychiatric syndrome characterised
by an acute disturbance in attention and awareness that
develops over a short period of time and cannot be accounted
for by any pre-existing or evolving neurocognitive disorder
(DSM-5). It can fluctuate in severity during the day with
symptoms aEecting diEerent areas of cognition including memory,
orientation, language, visual spatial ability and perception (Hosker
2016). Disruption of the sleep-wake cycle is common. There
are three subtypes of delirium: hyperactive; hypoactive; and
mixed (Fitzgerald 2017; Meagher 2008). Hyperactive delirium is
characterised by increased motor activity, loss of control of activity
and restlessness, and can be accompanied by agitation and
mood lability. Perceptual disturbances such as hallucinations and
delusions are more prevalent in hyperactive delirium. Hypoactive
delirium is characterised by decreased activity, decreased speed of
action, listlessness, reduced awareness or withdrawal, fatigue and
lethargy. Delirium of a mixed type alternates between hyperactive
and hypoactive forms (Meagher 2008; Meagher 2012). Hypoactive
delirium is the most commonly presented subtype in palliative care
(Meagher 2012; Spiller 2006); it is, however, more diEicult to identify
(Inouye 2001; Leonard 2014).
The aetiology of delirium is complex and commonly multifactorial
(Grassi 2015; Lawlor 2000; Rockwood 2008). Delirium may
arise from: severe pain; pneumonia; constipation; urinary tract
retention or infection; electrolyte abnormalities from dehydration
or renal failure; haematological abnormalities; endocrine or
metabolic factors such as thyroid dysfunction or nutritional
deficits; metabolic encephalopathy; paraneoplastic syndromes;
cerebral tumour or cerebrovascular disease; central nervous
system metastases; seizure disorders; myocardial infarction
or heart failure; and environmental factors such as sleep
deprivation and sensory deprivation, oNen secondary to
visual and hearing impairment. In addition, administration or
withdrawal of numerous drugs (such as alcohol and sedatives)
are known triggers of delirium. In terminally ill people,
opioids, antipsychotics, anticholinergic agents, corticosteroids and
antineoplastic agents can cause delirium (Caraceni 2009; Jackson
1999 ). Benzodiazepines, which are commonly used to treat
delirium, can also contribute to its cause (Clegg 2011; Zaal 2015).
Delirium is common in palliative care. Across all specialist palliative
care settings, the prevalence of delirium prior to death is 42%
to 88% (Watt 2019). In specialist palliative care inpatient settings
delirium prevalence varies with a range of 13% to 42% on
admission, 26% to 62% during admission, and 59% to 88% in
the weeks or hours preceding death (Hosie 2012). It can have
a deleterious impact on the person's quality of life, behaviour
and communication (Ganzini 2008), and is oNen highly distressing
for the person (O'Malley 2008; Partridge 2013) and their family
(Finucane 2017). For people with advanced disease, delirium
imposes an additional burden as it impedes communication
with families and obstructs participation in treatment decisions,
counselling and symptom assessment (Bush 2014; Lawlor 2000)
Delirium in terminally ill people can be treated by non-
pharmacological methods or by administering drug therapy,
or by a combination of both approaches (de Stoutz 1995;
Moyer 2011). Studies suggest that between one-third and one-
half of cases of delirium occurring in palliative care settings
are reversible (Lawlor 2000; Leonard 2008). Reversibility is
more likely for episodes precipitated by medications, electrolyte
abnormalities and infection; and less likely when delirium relates
to encephalopathy, organ failure or if delirium has previously
been experienced (Bush 2014; Leonard 2014). Treatment may
not, however, be possible in the last 24 to 48 hours of life
because of irreversible processes such as multiple organ failure
and metabolic abnormalities. Management becomes increasingly
challenging at this stage and the person may appear distressed
or suEer from heightened behavioural manifestations, such as
involuntary muscle twitching or jerks and restlessness. They may
also experience spiritual, emotional or physical anguish, anxiety
and cognitive failure. This combination of symptoms has been
described as agitated delirium at the end of life, refractory delirium,
terminal delirium, terminal restlessness, terminal agitation, or
terminal distress.
Description of the intervention
The first-line approach for managing delirium in terminally ill
adults, including those in the last 48 hours of life, is attention to
the underlying causes (Bush 2014; Grassi 2015; Irwin 2013). The
primary goal is the reversal of aetiological factors once they have
been identified. In palliative care, opioid rotation, discontinuation
of any drug that is contributing to delirium and management
of clinical situations, such as dehydration and hypercalcaemia,
are common interventions (Grassi 2015; NHS Scotland 2014; SIGN
2019). ONen the causes of delirium are multifactorial, hence the
complexity. Moreover, goals of care may preclude treatment: if the
person's goals of care are 'comfort only', then unpleasant or painful
diagnostic procedures or treatments may be avoided, and reversal
treatment need not be undertaken.
Non-pharmacological treatments include nursing the person in a
stable environment with continuity of care and a multidisciplinary
team approach (Cotton 2011; Inouye 2006; Inouye 2014). It also
involves the use of appropriate lighting for time of day, reduction
of noise, eEorts to establish a good diet and hydration, a regular
sleep pattern, analgesic review, adequate oxygen delivery, aids for
sensory impairment, mobilisation and, where possible, ensuring
the presence of a family member (Bush 2017; Morandi 2013;
Moyer 2011; NHS Scotland 2014). However, supportive techniques
alone are not always eEective in controlling symptoms of delirium
and a pharmacological intervention may be required. While non-
pharmacological strategies are most commonly used to manage
hypoactive delirium, a combination of non-pharmacological and
pharmacological strategies has been the dominant approach used
to manage hyperactive delirium (Morandi 2013).
Medications currently used to manage delirium symptoms
in clinical practice include antipsychotics (e.g. haloperidol,
olanzapine, chlorpromazine, risperidone and methotrimeprazine);
benzodiazepines (e.g. lorazepam and midazolam); and non-
benzodiazepine hypnotics and sedatives (e.g. melatonin and
dexmedetomidine). First generation antipsychotics (previously
known as ‘typical antipsychotics’) include butyrophenones
(e.g. haloperidol) and phenothiazines (e.g. levomepromazine/
methotrimeprazine and chlorpromazine). Second generation
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antipsychotics (previously known as ‘atypical’) include olanzapine
and risperidone while third generation antipsychotics include
aripiprazole. Haloperidol has been the ‘practice standard’
antipsychotic for delirium for many years due in part to familiarity
of use in clinical practice, less sedative eEects and versatility of
routes of administration (Breitbart 2000; Bush 2017; CCSMH 2010;
Ingham 1998; Lowe 2016; NHS Scotland 2014; NICE 2010; Roth
1996). Midazolam is the drug of first choice for sedation in the
management of refractory agitated delirium in the last two weeks
of life (Bush 2017; Maltoni 2012), especially when anxiety is present
(Twycross 2017).
Pharmacological interventions with a more sedating approach
or intermittent sedation is indicated where a person remains
agitated despite non-pharmacological strategies and appropriate
doses of minimally sedating antipsychotics (Bush 2014; Hosker
2016). Benzodiazepines are not generally recommended except for
lorazepam and midazolam in selected situations. The strategy of
combining a short-acting benzodiazepine with an antipsychotic
is oNen used in the management of severe refractory agitation
(Battaglia 2005; Ferraz Gonçalves 2016a; Ferraz Gonçalves 2016b;
NHS Scotland 2014). Palliative sedation may be an option to ensure
comfort in the final hours or days (Cherny 2014), although a
Cochrane Review examining sedation for terminally ill adults found
that despite sedation, delirium was still troublesome for people in
the last days of life (Beller 2015). Drug therapy to manage delirium
is not without controversy; there are, for instance, concerns that
some drug treatments for refractory symptoms may hasten death
(Lo 2005), though a review of the evidence on palliative sedation
for people with advanced cancer shows that sedation, when used
appropriately, has no eEect on survival (Maltoni 2012).
How the intervention might work
The role of antipsychotics for delirium in palliative care has evolved
from their role in psychiatric disorders with psychotic symptoms
and is based on some evidence of dopamine excess contributing
to delirium (Meagher 2017). In first generation antipsychotics
(e.g. haloperidol, chlorpromazine), dopamine blockade using
antipsychotics aims to reduce the hypothesised dopamine
excess in delirium. Dopamine blockade is only one aspect of
antipsychotic action, however; there are also side eEects — such
as cognitive impairment, functional decline, sedation, hypotension
and extrapyramidal eEects — due to anticholinergic activity and α
receptor blockade.
Second generation antipsychotics (e.g. olanzapine, risperidone,
quetiapine) are a class of drugs with a 5HT2A-D2 antagonism
that first generation antipsychotics do not have. The use of
second generation antipsychotics is increasingly common, with
one prospective observational study indicating that at least 50%
of hospitalised people with delirium were prescribed atypical
antipsychotics, in particular risperidone and quetiapine (Hatta
2014). The diEerent mechanism of action of second-generation
antipsychotics is thought to result in a safer profile such as
a reduced likelihood of extrapyramidal side eEects and better
tolerance, though more evidence relating to their eEects is needed
(Breitbart 2002; Grassi 2015).
Benzodiazepines, including midazolam and lorazepam, work in
the central nervous system, selectively occupying GABA (gamma-
aminobutyric acid) receptors. Benzodiazepines enhance responses
to the GABA inhibitory neurotransmitter by opening GABA-
activated chloride channels and allowing chloride ions to enter the
neuron. This results in the neuron becoming negatively charged
and resistant to excitation, resulting in anti-anxiety, sedative and
anti-seizure activity observed with these drugs (www.drugs.com).
Why it is important to do this review
Haloperidol, an antipsychotic agent with potent anti-dopaminergic
properties, is considered the drug of choice for the treatment
of delirium in terminally ill people (Bush 2017; Irwin 2013;
NHS Scotland 2014; Twycross 2017). Benzodiazepines, specifically
midazolam, are frequently used in practice to care for the
imminently dying person (Bush 2017; Maltoni 2012; Twycross 2017),
but evidence for their eEectiveness to manage delirium symptoms
is unclear. Previous reviews, drawing on studies involving palliative
and related populations, identify a lack of evidence for the
eEectiveness of drug therapy in the management of delirium (Bush
2017; Breitbart 2000; Caraceni 2009; de Stoutz 1995; Grassi 2015;
Inouye 2014; Irwin 2013; Moyer 2011). The previous version of this
Cochrane Review identified only one study (Candy 2012). Since
then new studies have been conducted and have stimulated debate
on the role and eEectiveness of antipsychotics to manage delirium
symptoms at the end of life (Meagher 2017). A national guideline
on the management of end-of-life care published by the National
Institute for Health and Care Excellence (NICE) in the UK in 2015
contains the following statement (NICE 2015).
“People oNen feel anxious in the last days of their life, and may
feel agitated or become delirious (when a person can be confused
or struggle to understand or remember, or their personality may
change). The doctor should check for possible causes and discuss
possible treatments with the person”.
In this review, we aim to assess the current evidence for the use of
pharmacological agents to manage delirium in this context.
O B J E C T I V E S
To evaluate the eEectiveness and safety of drug therapies to
manage delirium symptoms in terminally ill adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs evaluating a pharmacological intervention for delirium
symptoms in adults with terminal illness, compared to placebo,
usual care, or another intervention.
Types of participants
Terminally ill adults (18 years or older) with delirium symptoms.
This included trials whose participants were described as having
terminal agitation, terminal distress or terminal restlessness. Whilst
we relied on the trial authors’ description of a participant having
delirium, in all cases we sought to verify that the disorder being
treated qualified as a form of delirium as defined by Diagnostic
and Statistical Manual of Mental Disorders criteria (DSM-5 or earlier
versions), the short Confusion Assessment Method (Inouye 2003),
or a similar validated diagnostic tool such as the Memorial Delirium
Assessment Scale (MDAS) (Breitbart 1997).
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The definition of terminal illness is not always clear. For the
purpose of this review, the term 'terminally ill' includes any
adult with an advanced progressive illness including advanced
cancer, advanced dementia and organ failure (e.g. end-stage kidney
disease, advanced liver disease, advanced heart disease), as well as
those receiving hospice and end-of-life care. We included trials in
which participants were receiving supportive or symptom-oriented
care as opposed to disease-specific or restorative treatment.
Types of interventions
We included pharmacological interventions in any dose by any
route for the management of delirium symptoms compared with
another pharmacological intervention, a non-pharmacological
approach, placebo, standard care or wait-list control. Specific
pharmacological interventions could include: antipsychotics;
benzodiazepines; barbiturates; anti-epileptics; anti-depressants;
and other agents considered in the management of delirium.
Types of outcome measures
Primary outcomes
This review has three primary outcomes of interest.
1. Delirium symptoms within 24 hours and between 24 and 48
hours
2. Agitation score within 24 hours and between 24 and 48 hours
3. Number of adverse events, including extrapyramidal eEects
Secondary outcomes
1. Use of rescue medication, such as midazolam
2. Cognitive status
3. Survival
Search methods for identification of studies
To identify trials for inclusion we developed detailed search




1. Cochrane Central Register of Controlled Trials ‒ CENTRAL (CRSO)
searched on 10 July 2019
2. MEDLINE (OVID) 1946 to 8 July 2019
3. Embase (OVID) 1974 to 9 July 2019
4. CINAHL (EBSCO)1982 to 9 July 2019
5. PsycINFO (OVID) 1806 to 9 July 2019
Trial registers searched
1. ClinicalTrials.gov
2. ISRCTN Trials Register: www.isrctn.com
3. The Netherlands Trial Register: www.trialregister.nl/trialreg/
index.asp
4. UK Clinical Trials Gateway: www.ukctg.nihr.ac.uk
5. UMIN Japan Trial Register: www.umin.ac.jp/ctr
6. World Health Organization (WHO) Portal (covers
ClinicalTrials.gov; ISRCTN; Australian New Zealand Clinical Trials
Registry; Chinese Clinical Trial Register; Clinical Trials Registry
‒ India; German Clinical Trials Register; Iranian Registry of
Clinical Trials; Sri Lanka Clinical Trials Registry; The Netherlands
National Trial Register): www.who.int/trialsearch.
Pharmaceutical industry trials registers searched
1. AstraZeneca Clinical Trials: www.astrazenecaclinicaltrials.com
2. Daiichi Sankyo: www.daiichisankyo.com
3. Eisai: www.eisai.com





7. Roche Clinical Trial Protocol Registry: www.roche-trials.com
Searching other resources
Reference lists
We searched the reference lists and forward citations of review
articles and each study included in the review for additional studies
and references.
Unpublished data
We did not seek data from unpublished studies, or studies only
published as conference abstracts.
Conference abstracts
We searched the abstract books from the annual conferences of the
European Palliative Care Association 2003 to 2019.
Language
We included all relevant studies identified regardless of language
of publication.
Data collection and analysis
Selection of studies
For this update, six review authors (AMF, LJ, BL, ELS, PS,
BC) independently screened citations by title and abstract. We
retrieved the full texts for all articles deemed to be potentially
relevant. Two review authors (AMF and BC) independently screened
the full texts of studies retrieved. When uncertainty on study
inclusion occurred, we resolved it by discussion between all review
authors. We recorded reasons for exclusion of potential studies
screened at full-text review and provide a PRISMA flow diagram in
Figure 1 to illustrate the selection process (Moher 2009).
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Figure 1.   Review flow diagram.
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Data extraction and management
We extracted data using standard data extraction forms for
intervention reviews (Cochrane 2014). One author (AMF) extracted
data and another (BC) checked them. Data extraction forms
included: general publication information; study eligibility;
methods; participants; intervention groups; and primary and
secondary outcomes.
Assessment of risk of bias in included studies
We assessed the risk of bias of included trials in accordance with
the criteria described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We assessed these using
Cochrane's 'Risk of bias' instrument. The instrument assesses six
domains. We included sample size as a seventh domain. Two co-
authors (AMF and BC) independently assessed risk of bias, with a
third (BL) assisting in reaching a consensus relating to classification
where disagreements or uncertainty arose.
• Random sequence generation (selection bias). We assessed
the method used to generate the allocation sequence as: low
risk of bias (any truly random process: random number table;
computer random number generator); high risk of bias (odd
or even date of birth; hospital or clinic record number); and
unclear risk of bias (method used to generate sequence not
clearly stated).
• Concealment of allocation sequence (selection bias). The
method used to conceal allocation to interventions prior to
assignment determines whether intervention allocation could
have been foreseen in advance of, or during recruitment, or
changed aNer assignment. We assessed the methods as: low
risk of bias (telephone or central randomisation; consecutively
numbered, sealed, opaque envelopes); high risk of bias (open
list); and unclear risk of bias if the method was not clearly stated.
• Blinding of participants and personnel (performance bias). We
assessed the methods used to blind study participants and
personnel involved in delivering the intervention. We assessed
the methods as: low risk of bias if the study stated that it
was double blinded and described the method used to achieve
blinding, (e.g. identical tablets, matched in appearance and
smell); and unclear risk of bias if the study stated that it was
blinded but did not provide an adequate description of how
blinding was achieved. We judged a study as high risk if there
was no blinding or incomplete blinding, and the outcome was
likely to have been influenced by lack of blinding. We also judged
a study as high risk if blinding was attempted but it was likely
that the blinding could have been broken and the outcome was
likely to be influenced by lack of blinding.
• Blinding of outcome assessment (detection bias). We assessed
the methods used to blind outcome assessors as to which
intervention participants received. We assessed the methods
as: low risk of bias (e.g. study states that data collectors were
blinded to allocation, or outcome measures being assessed
were objective and not subject to bias); high risk (assessors were
not blinded and could have influenced outcome measures) or
unclear risk of bias (it was unclear and not stated anywhere that
the outcome assessors were blinded to treatment allocation).
• Incomplete outcome data (attrition bias). We assessed whether
there was attrition bias due to the amount, nature or handling
of incomplete outcome data. We judged the study as having low
risk of attrition bias if there were no missing outcome data or
the reasons for missing data were unlikely to be related to true
outcome, or missing data and reasons for it were similar across
trial arms. We judged the study as high risk if the reason for
missing outcome data could be related to the outcome, with
imbalance across trial arms in numbers or reasons for missing
data or if an inappropriate approach to handle missing data was
used (e.g. single imputation). We judged the study as unclear
risk if there was insuEicient reporting of attrition to permit
judgement of low or high risk.
• Selective outcome reporting. We assessed selective outcome
reporting, if a protocol was available, by comparing outcomes
in the protocol and published report. If they were the same we
assessed it as low risk in this domain, if they diEered significantly
we considered it as high risk. If a protocol was not available we
considered the study as having an unclear risk of bias.
• Sample size. Smaller studies are usually associated with higher
risk of bias. They are more likely to overestimate treatment
eEect and are at higher risk of confounders and of imbalance
between arms (Deschartres 2013; Zhang 2013). We classified
studies as being at low risk of bias (200 participants or more per
treatment arm); unclear risk of bias (50 to 199 participants per
treatment arm); or high risk of bias (fewer than 50 participants
per treatment arm).
Measures of treatment eDect
For continuous outcomes we sought to report, or calculate if not
reported in the paper, the mean diEerence (MD) between arms
and 95% confidence intervals (CIs). These were reported either as
changes from baseline or final mean at end-point. Should we have
found a mix of outcomes as final measurements and changes from
baseline we would have placed them in separate subgroups with
results of the subgroups pooled together.
For dichotomous outcomes, we sought to report, or calculate if not
reported in the paper, the risk ratios (RRs) and their 95% CIs based
on the number of participants with and without the outcome in
each arm. For survival analysis we reported the hazard ratio (HR)
and 95% CI as reported in the study or calculated if not reported.
We performed all analyses with Review Manager 5 (Review Manager
2014).
Unit of analysis issues
The unit of analysis was the individual participant. For cross-over
studies we planned to use first period data only where possible, but
otherwise to use available data and consider any potential bias that
this study design presented.
Dealing with missing data
Given the nature of this field, we expected significant loss to follow-
up in included trials due to participants' declining health. We report
attrition rates in the 'Risk of bias' tables. This included, if available,
per trial arm reasons for attrition and whether the trial stated any
re-inclusions performed in analyses.
If limitations in the trial data prevented reporting an RR, or an MD if
continuous data, we contacted the authors for information. Where
further information was unavailable we reported the results with
caution due to lack of transparency of the evidence. We did not
exclude trials on the basis of missing data.
Drug therapy for delirium in terminally ill adults (Review)
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Assessment of heterogeneity
If meta-analysis had been possible, we would have assessed
statistical heterogeneity between trials using the Chi2 test and the
I2 statistic. If heterogeneity was identified we planned to undertake
subgroup analysis to explore the lack of homogeneity.
Assessment of reporting biases
If meta-analysis had been possible we planned to explore
publication bias using funnel plots.
Data synthesis
If data from trials were suEiciently similar (in terms of population,
diagnostic criteria, intervention, outcome measure, length of
follow-up and type of analysis), we planned to combine data in a
meta-analysis to provide a pooled eEect estimate. We would use
a fixed-eEect model in the first instance. If there was no statistical
heterogeneity across trials, we would have used a random-eEects
model to check the robustness of the fixed-eEect model and both
models would have been reported. If statistical heterogeneity was
observed, we would have used the random-eEects model a priori.
No two studies compared the same treatments, and a meta-
analysis was not possible. Results were reported for each head-
to-head comparison, starting with the most common drug as
reference.
Subgroup analysis and investigation of heterogeneity
To explore clinical heterogeneity and investigate the eEect
modification of participants and treatment types, we planned,
if suEicient data had been available, to perform the following
subgroup analyses.
Participants
1. Type of disease, for example cancer, HIV or cardiovascular
disease
2. Age group
3. Type of delirium (hypoactive, hyperactive or mixed)
Intervention
1. Type of drug therapy
Sensitivity analysis
We planned, if suEicient data had been available, to perform
sensitivity analyses by excluding:
• studies with a higher risk of bias;
• studies that used scales that were not validated to measure
eEect.
Quality of evidence
We used the GRADE system to assess the quality of the evidence
related to the key outcomes listed in Types of outcome measures.
The GRADE system uses the following criteria for assigning grade of
evidence.
• High: we are very confident that the true eEect lies close to that
of the estimate of the eEect.
• Moderate: we are moderately confident in the eEect estimate;
the true eEect is likely to be close to the estimate of eEect, but
there is a possibility that it is substantially diEerent.
• Low: our confidence in the eEect estimate is limited; the true
eEect may be substantially diEerent from the estimate of the
eEect.
• Very low: we have very little confidence in the eEect estimate;
the true eEect is likely to be substantially diEerent from the
estimate of eEect.
The GRADE system uses the following criteria for assigning a quality
level to a body of evidence (Higgins 2011).
• High: randomised trials; or double-upgraded observational
studies.
• Moderate: downgraded randomised trials; or upgraded
observational studies.
• Low: double-downgraded randomised trials; or observational
studies.
• Very low: triple-downgraded randomised trials; or downgraded
observational studies; or case series/case reports.
Factors that may decrease the quality level of a body of evidence
are:
• limitations in the design and implementation of available
studies suggesting high likelihood of bias;
• indirectness of evidence (indirect population, intervention,
control, outcomes);
• unexplained heterogeneity or inconsistency of results (including
problems with subgroup analyses);
• imprecision of results (wide confidence intervals);
• high probability of publication bias.
Two review authors (BC and AMF) independently rated the quality
of the evidence for each primary outcome. We decreased the grade
rating by one (−1) or two (−2), up to a maximum of three (−3) if we
identified:
• serious (−1) or very serious (−2) limitations to study quality;
• important inconsistency (−1);
• some (−1) or major (−2) uncertainty about directness;
• imprecise or sparse data (−1);
• high probability of reporting bias (−1).
We were cognisant of inconsistencies, where point estimates might
vary widely across studies or confidence intervals (CIs), or where
studies showed minimal or no overlap (Guyatt 2011). Under such
circumstances, where there were substantial diEerences in adverse
event withdrawals, one would have no confidence in the result and
would need to downgrade the quality of the evidence by three
levels to very low quality (Guyatt 2013b).
In certain circumstances, we adjusted the overall rating for a
particular outcome as recommended by GRADE guidelines (Guyatt
2013a; Guyatt 2013b). For example, if there were so few data that
the results were highly susceptible to the random play of chance,
we would have no confidence in the result and we downgraded the
evidence to very low quality.
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Summary of findings
We include eight 'Summary of findings' tables for primary
outcomes as recommended in the Cochrane Handbook for
Systematic Reviews of Interventions (Schünemann 2017).
For the 'Summary of findings' tables we used the following
descriptors for levels of evidence (EPOC 2015).
• High: this research provides a very good indication of the
likely eEect. The likelihood that the eEect will be substantially
diEerent† is low.
• Moderate: this research provides a good indication of the
likely eEect. The likelihood that the eEect will be substantially
diEerent† is moderate.
• Low: this research provides some indication of the likely eEect.
However, the likelihood that it will be substantially diEerent† is
high.
• Very low: this research does not provide a reliable indication
of the likely eEect. The likelihood that the eEect will be
substantially diEerent† is very high.
† Substantially diEerent: a large enough diEerence that it might
aEect a decision.
R E S U L T S
Description of studies
Results of the search
In the original review (Jackson 2004), one study met the criteria
for inclusion (Breitbart 1996). No new studies were identified for
the 2012 update (Candy 2012). For this update we broadened the
search criteria and removed the population search terms 'terminal
or advanced disease or palliative' to reduce the risk of missing
potentially relevant papers. We also removed the date limiters to
allow re-screening of papers published prior to the last update
that may now be relevant given the broadened search strategy.
This search resulted in 10,445 citations aNer de-duplication. We
identified 43 potential studies for full-text review (Figure 1). ANer
assessment we excluded 37 complete studies and identified two
ongoing studies and one awaiting classification.
Included studies
Four trials met our criteria for inclusion: one study which was
included in earlier review versions (Breitbart 1996); and three new
studies (Agar 2017; Hui 2017; Lin 2008). Two were carried out in the
USA (Breitbart 1996; Hui 2017), one in Australia (Agar 2017), and one
in Taiwan (Lin 2008).
One study compared haloperidol, chlorpromazine and lorazepam
in the management of delirium in people hospitalised due to AIDS
(30 participants randomised) (Breitbart 1996).
One compared haloperidol and olanzapine in the management of
delirium in patients with advanced cancer receiving hospice and
palliative care (30 participants randomised) (Lin 2008).
One compared haloperidol, risperidone and placebo in the
management of delirium symptoms associated with distress in
patients receiving palliative care. Over 80% had cancer (249
participants randomised) (Agar 2017).
One compared lorazepam and placebo as an adjuvant to
haloperidol for persistent agitation associated with delirium in
patients with advanced cancer (90 participants randomised) (Hui
2017).
The Breitbart 1996 trial involving people with AIDS fulfilled our
criteria of terminal illness because the participants’ disease was at
an advanced stage in that they had developed various and multiple
moderate to severe medical co-morbidities that required medical
treatment.
See Characteristics of included studies for full details.
Delirium assessment
In all studies, a diagnosis of delirium was made using Diagnostic
and Statistical Manual of Mental Disorders (DSM) criteria. The
earliest study used the DSM-III-R (Breitbart 1996), while Lin 2008
used the DSM-IV and Agar 2017 and Hui 2017 used the DSM-IV
TR. Three of the four studies included additional eligibility criteria
for delirium. One study also required a Delirium Rating Scale
(DRS) score of 13 or more (Breitbart 1996), with higher scores
reflecting more severe delirium. One required a Memorial Delirium
Assessment Scale (MDAS) score of 7 or more (higher scores reflect
more severe delirium) and the presence of delirium symptoms
associated with distress (Agar 2017). One study required a history
of agitation and a Richmond Agitation-Sedation Scale (RASS) score
of 1 or more over the previous 24 hours (higher scores reflecting
greater agitation) (Hui 2017).
Delirium at baseline
Delirium severity at baseline varied across each study, from mild or
moderate in Agar 2017 to more severe (Hui 2017). In two studies,
baseline delirium severity was assessed by the Memorial Delirium
Assessment Scale (MDAS) (Agar 2017; Hui 2017). MDAS scores range
from 0 (no delirium symptoms) to 30 (severe symptoms). In Agar
2017 median MDAS scores were 15.1 in the risperidone group, 14.6
in the haloperidol group and 13.7 in the placebo group, reflecting
mild- to moderate-severity delirium at baseline. In contrast, in Hui
2017 median MDAS scores at baseline were much higher: 30.0 in the
lorazepam group, and 28.0 in the placebo group, reflecting more
severe delirium.
In two studies, the Delirium Rating Scale (DRS) (Trzepacz 1988) was
used to assess delirium severity at baseline (Breitbart 1996; Lin
2008). The maximum possible score on the DRS is 32; a score of
13 or higher distinguishes participants with delirium. In Breitbart
1996, participants had mean baseline delirium severity scores of
20.45 (SD = 3.45) in the haloperidol group, 20.62 (SD = 3.88) in
the chlorpromazine group, and 18.33 (SD = 2.58) in the lorazepam
group. In Lin 2008 participants had mean baseline delirium severity
scores of 17.56 (SD = 5.18) in the olanzapine group, and 16.50 (SD =
4.70) in the haloperidol group.
Performance status at baseline
Performance status at baseline was reported in three studies
(Agar 2017; Breitbart 1996; Hui 2017). The Karnofsky Performance
Status (KPS) indicator was used to assess performance status
in two studies (Breitbart 1996; Hui 2017), while the Australian
modified Karnofsky Performance Status indicator (AKPS) was used
in Agar 2017. Participants in Hui 2017 had a lower performance
status than in Agar 2017 and Breitbart 1996. In Hui 2017, 90%
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of participants in the lorazepam and haloperidol group and 93%
in the placebo and haloperidol group had KPS scores of 30 or
lower and were considered severely disabled and in need of
hospitalisation. In Breitbart 1996, mean KPS performance status
across all participants was 52.3 (SD = 21.3, range: 10 to 90), with
no diEerence across treatment groups. A score of 50 suggests that
the person requires considerable medical assistance and frequent
medical care but is not bed bound. In Agar 2017, median AKPS
performance scores were 40 (IQR 30 to 50) in both the risperidone
and placebo groups, and 50 (IQR 40 to 50) in the haloperidol group.
A score of 40 reflects being in bed at least 50% of the time.
Method of drug administration and dosage
Method of drug administration and dosage varied across studies.
Two studies used oral administration (Agar 2017; Lin 2008); one
study used intravenous administration (Hui 2017); and one used
oral or intramuscular administration (Breitbart 1996). The starting
dose of oral haloperidol in Agar 2017 was 0.5 mg for participants
aged 65 or younger, followed by 0.5 mg maintenance doses
every 12 hours. For participants over the age of 65 doses were
halved. Loading doses in Lin 2008 were higher, starting at 5 mg
of oral haloperidol. Loading doses were lower in Breitbart 1996,
with a dose of 0.25 mg for oral administration or 0.125 mg for
intramuscular administration. In contrast in Hui 2017, where the
primary outcome was agitation and participants had more severe
delirium, all participants received a dose of 2 mg of haloperidol
every four hours intravenously and another 2 mg as required,
followed by 3 mg of lorazepam or placebo once the participant met
the threshold for rescue medication.
Excluded studies
We excluded 37 studies following full-text retrieval, with reasons
given here: Characteristics of excluded studies. The most common
reasons for exclusion were that the participants were not terminally
ill or that the study was not a randomised controlled trial.
Ongoing studies
We identified two ongoing studies: see Characteristics of
ongoing studies. NCT03021486 evaluates haloperidol and/or
chlorpromazine for refractory agitated delirium in adults with
advanced cancer and is due for completion in 2021. NCT03743649
compares haloperidol and lorazepam in controlling symptoms
of persistent agitated delirium in patients with advanced cancer
undergoing palliative care and is due for completion in 2024.
Studies awaiting classification
We identified one recently completed trial comparing haloperidol
with olanzapine for the optimal management of delirium
symptoms in people with advanced cancer (van der Vorst 2019).
The full results of this trial had not been published at the time
the searches for the current review update were undertaken (July
2019). We are aware that this trial has since been published
(December 2019) and will consider it as part of the next update.
Risk of bias in included studies
Two review authors (AMF and BC) independently evaluated each
study using the Cochrane ‘Risk of bias’ tool (Higgins 2011), with a
third (BL) advising where uncertainties arose. The risk ratings for
each source of potential bias in included studies are shown in Figure
2, and the percentage of studies falling into each risk rating category
(low, unclear, and high) for each source of potential bias is shown
in Figure 3. Details and justification for each rating are included in
the Characteristics of included studies. All studies were vulnerable
to bias, most commonly bias due to small sample size, and all were
at high risk of bias on at least one criterion.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages




Two of the four studies described the method of random sequence
generation (Agar 2017; Hui 2017), and we judged these as being at
low risk of bias. We judged the other two studies as being at unclear
risk of bias for this domain.
Allocation concealment
Three studies reported the method of allocation concealment (Agar
2017; Breitbart 1996; Hui 2017), and we judged them to be at low
risk of bias. In one study, details were not provided and we judged
it to be at unclear risk of bias (Lin 2008).
Blinding
Performance bias
Three studies reported blinding of participants and study personnel
and we judged these as being at low risk of bias for this domain
(Agar 2017; Breitbart 1996; Hui 2017). Lin 2008 was an open study,
so personnel were not blinded, thus we made a judgement of high
risk of bias.
Detection bias
Three studies reported blinding of outcome assessors. We judged
two as being at low risk of bias (Agar 2017; Hui 2017), and one as
having unclear risk as it was an open study (Lin 2008). The fourth
study did not report this explicitly, but it was a double-blind study
and described procedures which suggested that outcome assessors
were likely to have been blinded, so we classed it as low risk for
detection bias (Breitbart 1996).
Incomplete outcome data
There was a high risk of attrition bias in two studies (Agar
2017; Lin 2008). In Agar 2017 the proportion of participants with
missing data for the primary outcome varied across trial arms:
risperidone (43/82, 52%), haloperidol (30/81, 37%) and placebo
(29/84, 34.5%). Reasons for discontinuation included deterioration
(31/247), inability to swallow (8/247), death (4/247) and other
reasons including family request. Twice as many participants
withdrew due to deterioration in the risperidone arm compared
with the other two. In Lin 2008, there were high rates of attrition:
11/16 (67%) dropped out in the olanzapine group and 7/14 (50%)
dropped out in the haloperidol group. In Breitbart 1996 there was
an unclear risk of bias due to limited information on attrition. Only
one study had a low risk of attrition bias (Hui 2017).
Selective reporting
The risk for reporting bias was low in two studies where protocols
were available, and outcomes reported were consistent with those
identified in the protocols (Agar 2017; Hui 2017). In two studies the
risk of reporting bias was unclear as no protocols were available
(Breitbart 1996; Lin 2008).
Other potential sources of bias
Three studies were of small size with fewer than 50 participants per
arm, and we classified these at high risk of bias (Breitbart 1996; Hui
2017; Lin 2008). One study had an unclear risk of bias with 50 to 199
participants per arm (Agar 2017).
EDects of interventions
See: Summary of findings for the main comparison Summary
of findings: haloperidol compared with placebo for delirium
in terminally ill adults; Summary of findings 2 Summary of
findings: haloperidol compared with risperidone for delirium in
terminally ill adults; Summary of findings 3 Summary of findings:
haloperidol compared with olanzapine for delirium in terminally ill
adults; Summary of findings 4 Summary of findings: risperidone
compared with placebo for delirium in terminally ill adults;
Summary of findings 5 Summary of findings: lorazepam plus
haloperidol compared with placebo plus haloperidol for delirium
in terminally ill adults; Summary of findings 6 Summary of
findings: haloperidol compared with chlorpromazine for delirium
in terminally ill adults; Summary of findings 7 Summary of
findings: haloperidol compared with lorazepam for delirium
in terminally ill adults; Summary of findings 8 Summary of
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findings: lorazepam compared with chlorpromazine for delirium in
terminally ill adults
Meta-analyses were not possible because of heterogeneity across
the trials. No two studies compared the same intervention.
Our primary outcomes were reported for most comparisons. Three
studies reported adverse events (Agar 2017; Breitbart 1996; Hui
2017). All three studies reported data on extrapyramidal eEects.
No study reported data on serious adverse events. Given that few
studies reported our secondary outcomes, and with such sparse
data, we did not assess GRADE for these outcomes as it would add
little to our overall evaluation.
1. Haloperidol versus placebo
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
There may be little or no diEerence between placebo and
haloperidol in managing delirium symptoms (MD 0.34, 95% CI −0.07
to 0.75; Analysis 1.1), based on data from 133 participants with
mild- to moderate-severity delirium in one study (Agar 2017). We
judged the quality of evidence as low. We downgraded the quality
of the evidence by two levels due to very serious study limitations
because of unclear risk of bias associated with sample size and
use of an unvalidated outcome measure (sub-scale of the Nu-DESC)
(Summary of findings for the main comparison).
Delirium symptoms between 24 and 48 hours of start of intervention
Haloperidol may lead to slightly increased delirium symptoms
compared with placebo (MD 0.49, 95% CI 0.10 to 0.88; Analysis
2.1), based on data from 123 participants with mild- to moderate-
severity delirium in one study (Agar 2017). We judged the quality
of evidence as low. We downgraded the quality of the evidence by
two levels due to very serious study limitations because of unclear
risk of bias associated with sample size and use of an unvalidated
outcome measure (sub-scale of the Nu-DESC).
Agitation score
Agitation between 24 and 48 hours of start of intervention
Haloperidol may reduce agitation slightly compared with placebo
(MD −0.14, 95% CI −0.28 to −0.00; Analysis 4.1), based on data from
123 participants with mild- to moderate-severity delirium in one
study over a period of one to three days (Agar 2017). We judged
the quality of evidence as low. We downgraded the quality of
the evidence by two levels due to very serious study limitations
because of unclear risk of bias due to sample size and imprecision
as the confidence interval includes zero.
Agitation between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Number of adverse events
Haloperidol probably slightly increases extrapyramidal adverse
eEects compared with placebo (MD 0.79, 95% CI 0.17 to 1.41;
Analysis 5.1), based on data from one study with 123 participants
with mild- to moderate-severity delirium (Agar 2017). In the same
study, there were no diEerences in parkinsonism and akathisia
and no serious extrapyramidal adverse eEects. No details were
provided on which extrapyramidal eEects were most pronounced.
Extrapyramidal eEects were not reported by time point. We judged
the quality of evidence on extrapyramidal eEects as moderate. We
downgraded the quality of the evidence by one level due to serious
study limitations because of unclear risk of bias due to sample size.
Use of rescue medication
Haloperidol or risperidone may increase slightly the use of rescue
midazolam for participants receiving antipsychotics compared
with placebo, based on data from participants with mild- to
moderate-severity delirium in one study (Agar 2017). For example,
day two: RR 2.04, 95% CI 1.12 to 3.71 (Analysis 6.1; analysis based
on data from haloperidol or risperidone arms combined compared
with placebo).
Cognitive status
Outcome not reported for this comparison.
Survival
In the one study that tested this comparison (Agar 2017), based
on data from 165 participants with mild- to moderate-severity
delirium, the proportion of participants who died during the 3-day
study intervention period was similar in the placebo (9/84) and
haloperidol arms (9/81). At 6-month follow-up, there was evidence
of a diEerence in overall survival favouring placebo compared with
haloperidol (HR 1.73, 95% CI 1.20 to 2.50; Analysis 6.6).
2. Haloperidol versus risperidone
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
There may be little to no diEerence between risperidone and
haloperidol in managing delirium symptoms (MD −0.42, 95% CI
−0.90 to 0.06; Analysis 1.2), based on data from 126 participants
with mild- to moderate-severity delirium in one study (Agar 2017).
We judged the quality of evidence as low. We downgraded the
quality of the evidence by two levels because of very serious study
limitations due to high risk of bias due to attrition and sample size
(Summary of findings 2).
Delirium symptoms between 24 and 48 hours of start of intervention
There may be little to no diEerence between risperidone and
haloperidol in reducing delirium symptoms (MD −0.36, 95% CI −0.92
to 0.20, Analysis 2.2), based on data from 106 participants with mild-
to moderate-severity delirium in one study (Agar 2017). We judged
the quality of evidence as low. We downgraded the quality of the
evidence by two levels because of very serious study limitations
due to high risk of bias due to attrition and sample size.
Agitation score
Agitation within 24 hours of start of intervention
Outcome not reported for this comparison.
Agitation between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Number of adverse events
Outcome not reported for this comparison.
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Use of rescue medication
Outcome not reported for this comparison.
Cognitive status
Outcome not reported for this comparison.
Survival
Outcome not reported for this comparison.
3. Haloperidol versus olanzapine
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
We are uncertain whether there is a diEerence between haloperidol
and olanzapine in managing delirium symptoms (MD 2.36, 95% CI
−0.75 to 5.47; Analysis 1.3) based on data from 28 participants in
one study (Lin 2008). We judged the quality of evidence as very low.
We downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance (Summary of findings 3).
Delirium symptoms between 24 and 48 hours of start of intervention
We are uncertain whether there is a diEerence between olanzapine
and haloperidol in reducing delirium symptoms (MD 1.90, 95% CI
−1.50 to 5.30; Analysis 2.3) based on data from 24 participants in
one study (Lin 2008). We judged the quality of evidence as very low.
We downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance.
Agitation score
Agitation within 24 hours of start of intervention
Outcome not reported for this comparison.
Agitation between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Number of adverse events
Outcome not reported for this comparison.
Use of rescue medication
We are uncertain whether there is a diEerence in use of rescue
medication with haloperidol compared with olanzapine based on
data involving 28 participants from one study (Lin 2008). Full data
were not available.
Cognitive status
Outcome not reported for this comparison.
Survival
Outcome not reported for this comparison.
4. Risperidone versus placebo
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
Risperidone may lead to slightly increased delirium symptoms
compared with placebo within 24 hours (MD 0.76, 95% CI 0.30 to
1.22; Analysis 1.4), based on data from 129 participants with mild-
to moderate-severity delirium in one study (Agar 2017). We judged
the quality of evidence as low. We downgraded the quality of the
evidence by two levels because of very serious study limitations
due to high risk of bias due to attrition and sample size (Summary
of findings 4).
Delirium symptoms between 24 and 48 hours of start of intervention
Risperidone may lead to slightly increased delirium symptoms
compared with placebo (MD 0.85, 95% CI 0.32 to 1.38; Analysis
2.4), based on data from 111 participants with mild- to moderate-
severity delirium in one study (Agar 2017). We judged the quality of
evidence as low. We downgraded the quality of the evidence by two
levels because of very serious study limitations due to high risk of
bias due to attrition and sample size.
Agitation score
Agitation within 24 hours of start of intervention
Outcome not reported for this comparison.
Agitation between 24 and 48 hours of start of intervention
There may be little to no diEerence in daily agitation scores for
placebo compared with risperidone (MD −0.05, 95% CI −0.19 to 0.09;
Analysis 4.2), based on data from 111 participants with mild- to
moderate-severity delirium in one study over a period of one to
three days (Agar 2017). We judged the quality of evidence as low. We
downgraded the quality of the evidence by two levels because of
very serious study limitations due to high risk of bias due to attrition
and sample size.
Number of adverse events
Risperidone may increase extrapyramidal adverse eEects
compared with placebo (MD 0.73, 95% CI 0.09 to 1.37; Analysis
5.3), based on data from one study with 111 participants with
mild- to moderate-severity delirium (Agar 2017). No details were
provided on which extrapyramidal eEects were most pronounced.
No serious extrapyramidal adverse eEects were reported. We
judged the quality of evidence on extrapyramidal eEects as low. We
downgraded the quality of the evidence by two levels because of
very serious study limitations due to high risk of bias due to attrition
and sample size.
Use of rescue medication
Reported above under Haloperidol versus placebo.
Cognitive status
Outcome not reported for this comparison.
Survival
In one study that tested this comparison (Agar 2017), based on data
from 166 participants with mild- to moderate-severity delirium,
the proportion of participants who died during the 3-day study
intervention period was lower in the placebo arm (9/84) compared
with the risperidone arm (16/82). At 6-month follow-up, there was
no evidence of a diEerence in overall survival in the placebo and
risperidone groups (HR 1.29, 95% CI 0.91 to 1.84; Analysis 6.7).
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5. Lorazepam as an adjunct to haloperidol versus placebo as
an adjunct to haloperidol
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
We are uncertain whether lorazepam as an adjunct to haloperidol
compared with placebo as an adjunct to haloperidol improves
delirium symptoms (MD 2.10, 95% CI −1.00 to 5.20; Analysis 1.5)
based on data from 50 participants with moderate to severe
delirium in one study (Hui 2017). We judged the quality of evidence
as very low. We downgraded the quality of the evidence by three
levels because there were so few data that the results were highly
susceptible to the random play of chance (Summary of findings 5).
Delirium symptoms between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Agitation score
Agitation within 24 hours of start of intervention
We are uncertain whether lorazepam as an adjunct to haloperidol
reduces agitation scores compared with placebo as an adjunct to
haloperidol within 24 hours (MD 1.90, 95% CI 0.90 to 2.80; Analysis
3.1). This was based on data from 52 participants with moderate to
severe delirium in one study (Hui 2017). We judged the quality of
evidence as very low. We downgraded the quality of the evidence
by three levels because there were so few data that the results were
highly susceptible to the random play of chance.
Agitation between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Number of adverse events
We are uncertain whether lorazepam as an adjunct to haloperidol
increases adverse events compared to placebo as an adjunct to
haloperidol, based on data from 31 participants with moderate
to severe delirium in one study (Hui 2017). The most common
extrapyramidal eEect in both trial arms was hypokinesia or
akinesia; but there was no diEerence in number of participants with
hypokinesia or akinesia (RR 0.70, 95% CI 0.19 to 2.63; Analysis 5.2).
Reasons for dropouts (one in haloperidol arm and three in placebo
arm) were not given. We judged the quality of evidence on number
of people with an increase in extrapyramidal eEects as very low.
We downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance.
Use of rescue medication
Lorazepam as an adjunct to haloperidol compared with placebo
as an adjunct to haloperidol may reduce the use of rescue
antipsychotics, based on data from 58 participants with moderate
to severe delirium in one study (Hui 2017). Median diEerence in
haloperidol equivalent daily dose of rescue antipsychotics was −1.0
mg, 95% CI −2.00 to 0.00 (Analysis 6.2).
Cognitive status
Outcome not reported for this comparison.
Survival
In the one study that tested this comparison, based on data from 58
participants with moderate to severe delirium (Hui 2017), at follow-
up there was no evidence of a diEerence in number of participants
who survived following treatment with lorazepam plus haloperidol
compared with placebo plus haloperidol (HR 1.20, 95% CI 0.70 to
2.20; Analysis 6.8).
6. Haloperidol versus chlorpromazine
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
Outcome not reported for this comparison.
Delirium symptoms between 24 and 48 hours of start of intervention
We are uncertain whether haloperidol reduces delirium symptoms
in comparison to chlorpromazine (MD 0.37, 95% CI −4.58 to 5.32;
Analysis 2.5), based on data from 24 participants in one study
(Breitbart 1996). We judged the quality of evidence as very low. We
downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance (Summary of findings 6).
Agitation score
Agitation within 24 hours of start of intervention
Outcome not reported for this comparison.
Agitation between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Number of adverse events
We are uncertain whether there is a diEerence in adverse
events following treatment with haloperidol compared with
chlorpromazine. In the one study that tested this comparison
in data from 24 participants (Breitbart 1996), no diEerence in
extrapyramidal eEects between participants in the comparison
arms was found (MD 0.46, 95% CI −4.22 to 5.14; Analysis 5.4).
The study did not report any withdrawals in the haloperidol or
chlorpromazine groups. We judged the quality of evidence on
number of people reporting extrapyramidal eEects as very low. We
downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance.
Use of rescue medication
Outcome not reported for this comparison.
Cognitive status
We are uncertain whether there is a diEerence in cognitive status by
day two between haloperidol and chlorpromazine (MD −1.04, 95%
CI −8.83 to 6.75; Analysis 6.3), based on data from 24 participants in
one study (Breitbart 1996).
Survival
Outcome not reported for this comparison.
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7. Haloperidol versus lorazepam
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
Outcome not reported for this comparison.
Delirium symptoms between 24 and 48 hours of start of intervention
We are uncertain whether haloperidol reduces delirium symptoms
in comparison to lorazepam (MD −4.88, 95% CI −9.70 to −0.06;
Analysis 2.6), based on data from 17 participants in one study
(Breitbart 1996). We judged the quality of evidence as very low. We
downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance. Only six participants were recruited
to the lorazepam arm and the results were susceptible to
overestimating or underestimating the treatment eEect (Summary
of findings 7).
Agitation score
Agitation within 24 hours of start of intervention
Outcome not reported for this comparison.
Agitation between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Number of adverse events
We are uncertain whether there is a diEerence in adverse events
following treatment with haloperidol compared with lorazepam.
In the one study that tested this comparison in data from
16 participants (Breitbart 1996), no diEerence in extrapyramidal
eEects between participants in the comparison arms was found
(MD −6.66, 95% CI −14.85 to 1.53; Analysis 5.5). We judged the
quality of evidence on number of people reporting extrapyramidal
eEects as very low. Data on extrapyramidal eEects in the lorazepam
group was based on only five participants. All who received
lorazepam developed treatment-limiting adverse events, including
over-sedation, disinhibition, ataxia and increased confusion. All
withdrew from the study because of these eEects, and this trial arm
was closed. We downgraded the quality of the evidence by three
levels because there were so few data that the results were highly
susceptible to the random play of chance.
Use of rescue medication
Outcome not reported for this comparison.
Cognitive status
We are uncertain whether there is a diEerence in cognitive status
by day two between haloperidol and lorazepam (MD 4.60, 95% CI
−5.12 to 14.32; Analysis 6.4), based on data from 17 participants in
one study (Breitbart 1996).
Survival
Outcome not reported for this comparison.
8. Lorazepam versus chlorpromazine
Delirium symptoms
Delirium symptoms within 24 hours of start of intervention
Outcome not reported for this comparison.
Delirium symptoms between 24 and 48 hours of start of intervention
We are uncertain whether lorazepam reduces delirium symptoms
in comparison to chlorpromazine (MD 5.25, 95% CI 0.38 to 10.12;
Analysis 2.7), based on data from 19 participants in one study
(Breitbart 1996). We judged the quality of evidence as very low. We
downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance. Only six participants were recruited
to the lorazepam arm and the results were susceptible to
overestimating or underestimating the treatment eEect (Summary
of findings 8).
Agitation score
Agitation within 24 hours of start of intervention
Outcome not reported for this comparison.
Agitation between 24 and 48 hours of start of intervention
Outcome not reported for this comparison.
Number of adverse events
We are uncertain whether there is a diEerence in adverse
events following treatment with lorazepam compared with
chlorpromazine. In the one study that tested this comparison in
data from 18 participants (Breitbart 1996), those who received
lorazepam developed treatment-limiting adverse events (MD 7.12,
95% CI −1.08 to 15.32; Analysis 5.6). We judged the quality of
evidence on number of people reporting extrapyramidal eEects
as very low. Data on extrapyramidal eEects in the lorazepam
group was based on only five participants. All who received
lorazepam developed treatment-limiting adverse events, including
over-sedation, disinhibition, ataxia and increased confusion. All
withdrew from the study because of these eEects, and this trial arm
was closed. No adverse events were noted in the chlorpromazine
arm (n = 13). We judged the quality of evidence as very low. We
downgraded the quality of the evidence by three levels because
there were so few data that the results were highly susceptible to
the random play of chance.
Use of rescue medication
Outcome not reported for this comparison.
Cognitive status
We are uncertain whether there is a diEerence in cognitive status by
day two between lorazepam and chlorpromazine (MD −5.64, 95% CI
−15.65 to 4.37; Analysis 6.5) based on data from 19 participants in
one study (Breitbart 1996).
Survival
Outcome not reported for this comparison.
D I S C U S S I O N
Summary of main results
We assessed the evidence on drug therapy for the management of
delirium in terminally ill adults. We found three new trials bringing
the total number of trials to four (399 randomised participants). No
two trials examined the same comparators so meta-analysis was
not possible. The heterogeneity in key characteristics across trials
made it diEicult to summarise findings. Participants diEered in
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severity of delirium at baseline, from mild to moderate in Agar 2017
to more severe in Hui 2017. For most comparisons there were fewer
than 50 participants. Measures used to assess delirium symptoms
and adverse events varied. Two trials assessed the eEect of drug
therapy on agitation but the results could not be synthesized as the
assessed comparisons and time points diEered. Most evidence was
low to very low quality.
1. Haloperidol versus placebo
We identified only one study comparing haloperidol with placebo
for the management of delirium (Agar 2017). Delirium was
measured using a sub-scale of a validated scale consisting of three
items: inappropriate behaviour; inappropriate communication;
illusions and hallucinations. There was low-quality evidence
that, compared with placebo, haloperidol may worsen delirium
symptoms of mild to moderate severity for terminally ill people
between 24 and 48 hours; and low-quality evidence that
haloperidol may reduce agitation slightly between 24 and 48 hours.
There was moderate-quality evidence that haloperidol probably
increases extrapyramidal eEects in adults with mild- to moderate-
severity delirium.
2. Haloperidol versus risperidone
We identified only one study comparing haloperidol with
risperidone for the management of delirium (Agar 2017). Delirium
symptoms were measured using a sub-scale of a validated scale
consisting of three items: inappropriate behaviour; inappropriate
communication; illusions and hallucinations. Participants had
mild- to moderate-severity delirium. There was low-quality
evidence of little to no diEerence in delirium symptoms for
haloperidol compared with risperidone for terminally ill people
within 24 hours and between 24 and 48 hours. Agitation scores and
adverse events were not reported.
3. Haloperidol versus olanzapine
We identified only one small study comparing haloperidol with
olanzapine for the management of delirium (Lin 2008). Delirium
symptoms were measured using the Chinese version of the
Delirium Rating Scale. We are uncertain whether haloperidol
reduces delirium symptoms compared with olanzapine within 24
hours or between 24 and 48 hours. Agitation scores and adverse
events were not reported. Evidence was very low quality.
4. Risperidone versus placebo
We identified only one study comparing risperidone with
placebo for the management of delirium (Agar 2017). Delirium
symptoms were measured using a sub-scale of a validated scale
consisting of three items: inappropriate behaviour; inappropriate
communication; illusions and hallucinations. Participants had
mild- to moderate-severity delirium. There was low-quality
evidence that risperidone may worsen delirium symptoms of mild
to moderate severity for terminally ill people within 24 hours and
between 24 and 48 hours; and low quality evidence of little to
no diEerence in agitation scores for risperidone compared with
placebo between 24 and 48 hours. Evidence that risperidone may
increase extrapyramidal eEects was also low quality.
5. Lorazepam plus haloperidol versus placebo plus haloperidol
We identified one small study comparing lorazepam as an
adjunct to haloperidol with placebo as an adjunct to haloperidol
for the management of delirium (Hui 2017). Participants were
terminally ill people with moderate to severe delirium symptoms.
Delirium symptoms were measured using the Memorial Delirium
Assessment Scale (MDAS). Lorazepam as an adjunct to haloperidol
resulted in no diEerences in delirium symptoms or adverse
eEects, but greater reductions in agitation in participants with
agitated delirium, in comparison to haloperidol alone eight
hours aNer baseline. However due to the small number of
participants, evidence was very low quality. We remain uncertain
whether lorazepam plus haloperidol compared with placebo plus
haloperidol improves delirium symptoms within 24 hours, reduces
agitation or increases adverse events.
6. Haloperidol versus chlorpromazine
We identified one small study comparing haloperidol with
chlorpromazine for the management of delirium (Breitbart 1996).
Delirium symptoms were measured using the Delirium Rating
Scale. We are uncertain whether haloperidol reduces delirium
symptoms at 48 hours or increases adverse events compared with
chlorpromazine. Delirium symptoms at 24 hours and agitation
scores were not reported. Evidence was very low quality.
7. Haloperidol versus lorazepam
We identified one small study comparing haloperidol with
lorazepam for the management of delirium (Breitbart 1996).
Delirium symptoms were measured using the Delirium Rating
Scale. Only six participants were recruited to the lorazepam arm;
use of lorazepam was halted early due to treatment-limiting
adverse events. We are uncertain whether haloperidol reduces
delirium symptoms at 48 hours or increases adverse events
compared with lorazepam. Delirium symptoms at 24 hours and
agitation scores were not reported. Evidence was very low quality.
8. Lorazepam versus chlorpromazine
We identified one small study comparing lorazepam with
chlorpromazine for the management of delirium (Breitbart 1996).
Only six participants were recruited to the lorazepam arm; use
of lorazepam was halted early due to treatment-limiting adverse
events. Delirium symptoms were measured using the Delirium
Rating Scale. We are uncertain whether lorazepam reduces delirium
symptoms at 48 hours or increases adverse events compared with
chlorpromazine. Delirium symptoms at 24 hours and agitation
scores were not reported. Evidence was very low quality.
Secondary outcomes
There were insuEicient data to draw conclusions or assess the
quality of the evidence.
Three studies measured use of rescue medication; data could not
be synthesized, however, due to diEerent comparisons, diEerent
rescue medication used, diEerent drug dosages and diEerent
levels of baseline delirium severity across studies. In one study of
participants with mild- to moderate-severity delirium, there was
lower use of rescue medication in the placebo group compared with
the haloperidol or risperidone groups (Agar 2017). In a study of 30
participants comparing haloperidol and olanzapine there was no
diEerence in use of rescue medication (Lin 2008), whereas in Hui
2017, participants receiving lorazepam as an adjunct to haloperidol
had lower use of rescue medication compared to participants
receiving placebo as an adjunct to haloperidol.
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Only one small study measured cognitive status (Breitbart 1996),
and no diEerences in this outcome were reported between the
haloperidol, lorazepam and chlorpromazine groups.
Survival was reported in two studies (Agar 2017; Hui 2017), but
data could not be synthesized as comparisons diEered across
the two trials, and findings were inconsistent. Agar 2017 reported
no diEerence in survival for participants receiving placebo in
comparison to haloperidol during the 3-day study intervention
period, but better overall survival for those in the placebo group
at 6-month follow-up. Agar 2017 also reported that a much
higher proportion of those receiving risperidone compared with
placebo died during the 3-day intervention period; but reported no
diEerence in overall survival at six months for participants receiving
risperidone compared with placebo. In participants with moderate
to severe delirium, Hui 2017 found no evidence for a diEerence
in overall survival for those receiving lorazepam as an adjunct to
haloperidol compared with placebo as an adjunct to haloperidol.
In both studies reporting survival, there was no mention of whether
survival outcomes were explicitly due to the intervention.
Overall completeness and applicability of evidence
We searched five citation databases, six trial registers and seven
pharmaceutical industry trial registers to identify studies for this
update. We used translators where required to screen abstracts
in other languages so we were not limited to English language
publications. We identified 43 potentially eligible studies resulting
in a total of four included studies and a further two in progress
(NCT03021486; NCT03743649), and one complete but yet to be
classified (van der Vorst 2019). Included studies were conducted in
Australia (Agar 2017), the USA (Breitbart 1996 and Hui 2017), and
Taiwan (Lin 2008).
For this update, we extended the search strategy to search for
studies involving participants with any advanced illness (e.g.
advanced cancer, advanced dementia); end-stage disease (e.g.
end-stage kidney disease, HIV, advanced liver disease, advanced
heart disease); and those receiving hospice or palliative care. We
included studies in which participants were receiving supportive
or symptom-oriented care as opposed to disease-specific or
restorative treatment. Our broad definition of terminal illness,
in line with the WHO 2018, allowed us to identify studies
involving participants with any type of life-limiting advanced
progressive illness. We excluded studies in critical care settings,
as the goal of treatment diEers from that in palliative settings,
and is generally survival oriented as opposed to addressing
symptom management. Despite adopting a broad definition of
palliative care, we only identified studies involving participants
with advanced cancer (Agar 2017; Hui 2017; Lin 2008) and AIDS
(Breitbart 1996). This limits applicability of findings to adults with
only these advanced illnesses. Evidence for eEectiveness of drug
therapy and occurrence of adverse events may diEer for adults with
other illnesses or co-morbidities.
Meta-analyses were not possible because of heterogeneity across
the studies as no two studies compared the same intervention.
Due to the small number of heterogeneous studies, all of the
evidence described is based on single comparisons. The evidence
that placebo results in fewer delirium symptoms compared to
risperidone or haloperidol is based on a single study involving
participants with mild- to moderate-severity delirium, and needs to
be replicated to strengthen confidence in the estimates of eEects
reported.
Haloperidol was the most commonly evaluated drug, and
was examined in three studies. Lorazepam was evaluated
in two studies. Chlorpromazine, risperidone and olanzapine
were each evaluated in one study. The evidence to date
relates specifically to these antipsychotics and benzodiazepines.
Evidence from RCTs involving terminally ill adults for the
eEectiveness of other antipsychotics (e.g. quetiapine, aripiprazole,
levomepromazine/methotrimeprazine) and benzodiazepines (e.g.
midazolam) commonly used to manage delirium in palliative care
practice was not identified.
Baseline delirium varied across studies ranging from mild- to
moderate-severity delirium in Agar 2017 to more severe levels
of delirium amongst participants in Hui 2017. The evidence
that placebo results in fewer delirium symptoms compared to
haloperidol or risperidone relates to delirium symptoms of mild
to moderate severity, and cannot be extended to severe delirium.
Similarly, the evidence that lorazepam as an adjunct to haloperidol
is more eEective than haloperidol alone is from adults with severe
refractory agitated delirium, and is not applicable to those with
mild delirium.
Method of drug administration and dosage varied across studies.
The loading doses for haloperidol in the most recent studies reflect
current guidelines (Agar 2017; Hui 2017). However, the loading
dose for lorazepam in Hui 2017 (3 mg) reflects a higher dose than
recommended in guidelines which suggest doses of 0.5 mg to 1 mg
lorazepam orally or sublingually (NHS Scotland 2014; SIGN 2019).
DiEerences in the drug dose used limit the applicability of the
findings.
The scales used to assess delirium symptoms varied across studies.
In three studies delirium symptoms were reported using validated
scales (Delirium Rating Scale (DRS) or the Memorial Delirium
Assessment Scale (MDAS)). In Agar 2017, a sub-scale of the Nursing
Delirium Screening Scale (Nu-DESC) containing three items relating
to distressing delirium symptoms — inappropriate behaviour;
inappropriate communication; and illusions and hallucinations
— was used as the primary outcome. The Nu-DESC has been
validated (Gaudreau 2005); however the sub-scale used to assess
the primary outcome reported in Agar 2017 has not. MDAS scores
were not reported in Agar 2017, although the study authors state
that there was evidence of a diEerence in MDAS scores per day
favouring placebo over risperidone (but not haloperidol). Evidence
favouring placebo over antipsychotics relates to distressing
delirium symptoms, and is not applicable to symptoms associated
with hypoactive or mixed delirium.
Not all outcomes evaluated in the four included studies are
discussed in this review. Other outcomes reported in the four
studies, but unrelated to our primary and secondary outcomes,
were: general symptom severity (not delirium specific); patient
comfort; recall of delirium symptoms; distress recorded by family
caregivers and bedside nurses; duration of stay in palliative care
unit; and psychiatric condition. Some of these outcomes (e.g.
patient comfort and distress) may be of particular importance to
terminally ill adults and family carers, and should be considered as
outcomes for future trials. We will consider adding more outcomes
to future updates of our review.
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We identified two trials as currently in progress (NCT03021486;
NCT03743649) and one study currently awaiting classification
(van der Vorst 2019). NCT03021486 compares haloperidol with
chlorpromazine for refractory agitated delirium. Participant
recruitment commenced in June 2017, and the trial is expected
to reach completion in 2021. NCT03743649 compares haloperidol,
lorazepam and placebo to treat symptoms of persistent agitated
delirium in patients with advanced cancer. This trial commenced
in May 2019 and is due for completion in 2024. The results
of these two ongoing studies may aEect our conclusions. van
der Vorst 2019 compares the eEectiveness of olanzapine with
haloperidol in people with advanced cancer who were diagnosed
with delirium. This is now complete and has been published but
the full results had not been published when we conducted the
searches for the present update; they reported no diEerences
in delirium response rate following treatment with olanzapine
compared with haloperidol, and their findings would not change
the overall conclusions of this update.
Quality of the evidence
Conducting trials involving terminally ill adults is challenging
(Grande 2000), and none of the trials were unequivocally at low risk
of bias for all criteria. Three of the four included studies had a high
risk of bias due to small sample size (fewer than 50 participants
per trial arm). Two were at high risk of attrition bias given the
high proportion of withdrawals (Agar 2017; Lin 2008). Evidence for
all outcomes was based on single comparisons from individual
studies, as no two comparisons were examined across studies,
and generally there were so few data that the results were highly
susceptible to the random play of chance. For these reasons, our
GRADE judgements were low or very low quality for nearly all
primary outcomes. Very low quality means that this research does
not provide a reliable indication of the likely eEect. The likelihood
that the eEect will be substantially diEerent is very high.
Given that so few studies reported our secondary outcomes, and
with such sparse data, we did not conduct a GRADE assessment as
it would add little to our overall evaluation.
Potential biases in the review process
We sought trial evidence widely, including five citation databases,
six trial registers and seven pharmaceutical company trial registers
for this update. Furthermore we did not exclude non-English
studies and used a translator when required to translate key
information for articles written in another language. We only
included RCTs. Given that we limited our search to published
studies, there may be a risk of publication bias — studies may
be more likely to be published if they have a positive result.
However, publication bias was unlikely as our review includes
studies reporting no diEerence in our primary outcomes at one or
both time points.
All the outcomes reported are based on single studies and
comparisons, so we were unable to pool the data for meta-analysis.
Three of the four included studies were at high risk of bias due
to small sample size. We were unable to conduct a network meta-
analysis as the clinical characteristics of the study populations
varied, drug administration protocols diEered, and overall data
were sparse.
Agreements and disagreements with other studies or
reviews
This Cochrane Review update specifically examined the evidence
from RCTs for drug therapy to manage delirium in palliative
care settings. We identified few studies, as was the case in the
original Cochrane Review and the earlier update (Jackson 2004 and
Candy 2012 respectively), which highlights the continued dearth of
research in this area. This lack of evidence has been noted in other
related recent systematic and narrative reviews (Bush 2014; Bush
2018; Cerveira 2017; Grassi 2015; Inouye 2014; Sanchez-Roman
2014).
A number of non-Cochrane systematic reviews have been
conducted (e.g. Bush 2018; Bush 2014; Grassi 2015; Lawley 2017;
Sanchez-Roman 2014). Bush 2014 identified 15 prospective cohort
studies, plus 15 RCTs and one post hoc analysis of an RCT examining
antipsychotic medications for the management of delirium. Only
one of the included studies was specifically concerned with
delirium in the context of terminal illness. Their review concluded
that the evidence base is limited by lack of good quality RCTs,
and practice is oNen guided by expert opinion and guidelines.
Bush 2018 identified only three RCTs focused on pharmacological
interventions for delirium treatment in adults with cancer, only two
of which examined data for adults with terminal illness (Agar 2017;
Hui 2017). Lawley 2017 included seven studies in an integrative
review of the management of delirium in people with advanced
cancer. None, however, were RCTs; all were non-blinded and non-
randomised, and the authors concluded that there was no evidence
to guide best practice. In another systematic review of delirium in
palliative care settings, Sanchez-Roman 2014 identified only one
study focused on the use of drug therapy to manage delirium in
terminally ill adults; that, however, was a retrospective descriptive
study, leading the authors to conclude that evidence on delirium in
palliative care is limited.
Two other systematic reviews, including one Cochrane Review,
have concluded that current evidence does not support the use
of antipsychotics for the management of delirium in hospitalised
adults (Burry 2018; Neufeld 2016). Neufeld 2016 included studies
of any design (prospective or historical cohort, case-control,
and other observational designs) in hospital settings. Based on
data from 19 studies, their review showed that antipsychotic
use was not associated with change in delirium severity, nor
was there any association with mortality. Similarly, a Cochrane
Review identified nine studies (randomised or quasi-randomised
design) in hospital settings (Burry 2018), including two of the
studies reported in the present review. Burry 2018 concluded
that antipsychotics did not reduce the severity of delirium, or
resolve symptoms compared to non-antipsychotics or placebo.
Adverse events were rarely reported. In contrast, based on a
review of data from 15 RCTs involving hospitalised adults, Kishi
2016 concluded that antipsychotics were superior to placebo
in managing delirium symptoms, and that second-generation
antipsychotics were associated with fewer extrapyramidal eEects.
Six of the studies included in the Kishi 2016 review were included in
the Burry 2018 Cochrane Review. However, Kishi 2016 also included
four conferences abstracts and five studies that were not included
in Burry 2018; while Burry 2018 included three studies that were not
included in the Kishi 2016 review. Thus the evidence from which the
conclusions were drawn diEers across reviews.
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There is little evidence supporting the use of drug therapy for
sedation to control symptoms of refractory delirium in terminally
ill adults. Beller 2015, a Cochrane Review evaluating palliative
sedation in terminally ill people, identified four studies comparing
symptoms of sedated and non-sedated participants. None of
the evidence came from RCTs and overall the quality of the
evidence was low. Findings showed that despite sedation using
benzodiazepines (frequently midazolam), delirium symptoms
remained troublesome at the end of life, and were significantly
worse for those in the sedated group. In the present review we
identified very low quality evidence comparing lorazepam as an
adjunct to haloperidol with placebo as an adjunct to haloperidol.
This was based on one small study specific to terminally ill adults
with severe refractory agitated delirium and we remain uncertain
whether lorazepam as an adjunct to haloperidol improves delirium
or agitation in terminally ill adults with moderate to severe
delirium.
One network meta-analysis examined pharmacological
intervention for the management and prevention of delirium in any
care setting (Wu 2019). Network meta-analysis allows conclusions
to be drawn from multiple direct and indirect comparisons. This
analysis consisted of 58 studies of which 20 RCTs with a total
of 1435 participants compared the outcomes of management
of delirium. These included participants with diEerent health
conditions including cancer and AIDS; those hospitalised in
general wards or ICUs; elderly people with delirium; patients who
underwent major surgical procedures; and those in a hospice
setting. Wu 2019 concluded that the combination of haloperidol
plus lorazepam is the most eEicacious management for delirium.
However of the 20 RCTs included, only one small study directly
compared haloperidol plus lorazepam with placebo (Hui 2017).
Direct pairwise comparisons were not available. Furthermore,
heterogeneity, as noted by the study authors and supporting
editorial (Blazer 2019), needs to be considered in interpretation
of their results. Heterogeneity was present across RCTs, including
diEerent populations, outcome measures and methods of drug
administration. Consequently, further research is required before
conclusions can be drawn. In patients with advanced disease,
research in delirium is ongoing. Three trials are in-progress
or currently awaiting classification and will provide additional
evidence on the management of persistent agitated delirium
symptoms in a terminally ill population (van der Vorst 2019;
NCT03743649; NCT03021486).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For adults with a terminal illness
This review found no high-quality evidence to support or refute
the use of drug therapy for delirium symptoms in terminally ill
adults. There is low-quality evidence that drug therapy, compared
with placebo, worsens delirium symptoms in terminally ill people
with mild- to moderate-severity delirium, but our confidence in
the eEect estimate is limited. The true eEect may be substantially
diEerent from the estimate of the eEect. There is moderate- to
low-quality evidence that drug therapy for mild- to moderate-
severity delirium may slightly increase extrapyramidal side eEects
compared to placebo, but the likelihood that the eEect is
substantially diEerent is moderate to high.
For clinicians
We found no evidence of benefit associated with haloperidol
or risperidone for the management of delirium symptoms in
terminally ill adults with mild- to moderate-severity delirium. There
is low-quality evidence that haloperidol or risperidone may worsen
delirium symptoms compared with placebo for adults with mild-
to moderate-severity delirium. There is moderate-quality evidence
that haloperidol for mild- to moderate-severity delirium probably
slightly increases extrapyramidal side eEects compared to placebo;
and low-quality evidence that risperidone may slightly increase
extrapyramidal side eEects. There is very low quality evidence that
lorazepam with haloperidol may be more eEective than haloperidol
alone for the management of agitation in people with severe
delirium, but we are uncertain of this.
There remains insuEicient evidence on the eEectiveness and
harms of drug therapies for delirium in terminally ill adults.
The NICE 2010 guideline focuses on hospitalised adults, and
specifically excludes recommendations for those receiving end
of life care. Clinical guidelines recommend identifying reversible
causes of delirium and using non-pharmacological approaches
before pharmacological management (Bush 2018; CCSMH 2010;
CCSMH 2014; NHS Scotland 2014; SIGN 2019). This includes
reviewing all medication and stopping non-essential drugs,
maintaining hydration, controlling pain, promoting good sleep
patterns, re-orientating the person frequently, improving oral
nutrition and mobility, checking for opioid toxicity, checking for
infection, constipation and urinary problems, and reviewing the full
blood count and biochemistry.
If pharmacological intervention is essential to control symptoms,
then the aims of management should be determined by the
multi-professional team and the person’s family or supporters. In
adults with advanced cancer who are near to death, experiencing
severe distress and suEering, and whose symptoms of delirium
are not relieved by standard approaches, a clinician may
consider following the European Society for Medical Oncology
recommended framework for the use of sedation in palliative care
(Cherny 2014).
For policy makers
There is no high-quality evidence to support or refute the use of
drug therapy for delirium in terminally ill adults. There is low-
quality evidence that terminally ill people with mild- to moderate-
severity delirium do not benefit from risperidone or haloperidol,
but our confidence in the eEect estimate is limited and the true
eEect may be substantially diEerent from the estimate of the eEect.
For funders of the intervention
There is no high-quality evidence to support or refute the use of
drug therapy for delirium in terminally ill adults. There is low-
quality evidence that terminally ill people with mild- to moderate-
severity delirium do not benefit from risperidone or haloperidol,
but our confidence in the eEect estimate is limited and the true
eEect may be substantially diEerent from the estimate of the eEect.
Implications for research
For researchers
There is an urgent need for research to determine the eEectiveness
and harms of drug therapy for delirium in terminally ill adults. There
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is a requirement for research examining the eEectiveness of drug
therapy on diEerent delirium sub-types: hypoactive, hyperactive
and mixed. We did not identify any study examining drug therapy
for hypoactive delirium, even though this is the most common form
of delirium experienced by terminally ill people (Meagher 2012).
Research is also needed on the role of targeted PRN (as needed) use
of antipsychotics as opposed to scheduled antipsychotics.
There is a need for evidence on the eEectiveness of haloperidol
compared with placebo and other drug therapies. Haloperidol is
recommended as the first line of treatment for terminally ill people
with delirium (NHS Scotland 2014; Twycross 2017); the evidence
base underlying this recommendation is limited, however, and is
drawn from studies of people who are not terminally ill. Given low-
quality evidence that haloperidol may worsen delirium symptoms
amongst terminally ill people with mild to moderate delirium,
evidence regarding the contexts in which haloperidol is eEective is
needed.
There is some evidence from other populations that second
generation antipsychotics are as eEective as haloperidol in
managing delirium (Wang 2013), with fewer adverse events, and
are recommended in some guidelines (CCSMH 2010; CCSMH 2014).
We identified only two studies evaluating a second-generation
antipsychotic (Agar 2017; Lin 2008); additional studies are now
warranted.
Further research is needed on the multimodality management of
delirium, specifically the combination of non-pharmacological and
pharmacological interventions. This is important given that current
guidelines advocate using non-pharmacological interventions
before and alongside pharmacological approaches to prevent and
manage delirium (Bush 2018; NHS Scotland 2014; SIGN 2019).
Further research to inform future guideline development regarding
what combinations of interventions are most eEective, when and
for whom, is required.
Midazolam is recommended as a first line treatment for refractory
agitated delirium in the context of palliative sedation in the last
days or weeks of life (Bush 2017; Irwin 2013; Twycross 2017), but
has not been specifically evaluated as an intervention to manage
delirium. Clinical guidance recommends that midazolam is used
alongside haloperidol to treat terminal agitation when anxiety is
present (Twycross 2017); however no RCTs have examined this.
Evidence on the eEectiveness of midazolam is needed to clarify
its role in delirium management and understand better when it is
most, and least, eEective.
In line with the WHO 2018, we adopted a broad definition of
palliative care in searching for eligible studies. We identified three
studies involving adults with advanced cancer, and one with
AIDS. There is a need for studies involving participants with other
advanced progressive conditions, in particular advanced dementia,
given its prevalence (Etkind 2017), and the complexities associated
with identifying and managing delirium in this population.
We identified only four RCTs, reflecting the challenges of
conducting clinical trials involving terminally ill people, in
particular when people are unable to consent to research
participation. There is a growing body of literature suggesting that
some terminally ill people welcome the opportunity to take part in
research and benefit from doing so (Middlemiss 2015). Agar 2017
has also shown for the first time that an evaluation of drug therapy
compared with placebo is possible in a terminally ill population.
Studies including a placebo or best supportive care arm need to
be prioritised. It is vital that terminally ill people with delirium are
not excluded from participating in delirium research studies, whilst
ensuring that appropriate safeguards are in place (Sweet 2014).
People with delirium will usually be unable to consent themselves;
consequently procedures for advance consent and consent-by-
proxy are essential.
We considered network meta-analysis (NMA). This would
have allowed assessment of the relative eEectiveness of
several interventions synthesizing evidence across a network of
randomised trials. A key assumption underpinning the validity
of the approach is that there are no important diEerences in
trials included other than the treatments being compared (Cipriani
2013). We deemed our data unsuitable for network meta-analysis
for several reasons including important diEerences in the clinical
characteristics of participants across studies; diEerences in the
drug administration; and the small number of studies resulting
in sparse connections between each intervention. Consequently
there was a high likelihood that network meta-analysis would yield
imprecise results and we decided that reporting the individual
study results was more meaningful. We suggest that as further RCTs
are conducted, authors of future updates and related systematic
reviews revisit the potential of conducting network meta-analysis
to synthesize evidence and assess relative eEectiveness of diEerent
interventions across a network of studies.
For design
Attrition rates in the included studies and the relatively small
numbers of eligible participants in any one palliative care
treatment unit suggest that future studies should involve
participants recruited from multiple centres. Further eEorts should
be made to limit attrition, and outcomes should be collected even
when participants stop receiving the allocated treatment.
For measurement
Future research should carefully consider which outcome measures
are most important to terminally ill patients and their families and
carers. For instance, outcomes such as patient comfort or patient
and carer distress may become more important than resolution of
delirium symptoms as end of life approaches. Such outcomes need
to be identified, validated and prioritised for assessment alongside
delirium severity using valid scales.
The Nu-DESC has been validated, but the composite score based
on three Nu-DESC items has not been validated, and focuses
on assessment of distressing delirium symptoms. This sub-scale
should be validated before it is used as a primary outcome measure
in future studies. Specific outcome measures to assess distress
related to hypoactive delirium may also be required.
Survival was assessed in two studies, yet death is expected in
terminally ill patients, and it is diEicult to determine whether
survival/death is associated with the intervention, or a natural
occurrence given the study population. Further clarity on how
survival outcomes are to be interpreted are required in future
studies. A core outcome set for delirium studies is warranted.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomized clinical trial, multi-site, placebo-controlled, double-blind, parallel groups, dose-titrated
Study duration: 72 hours from randomisation, with follow-up for 6 months
Location: Australia
Participants Total: 249 participants randomised. 2 removed as ineligible. Sample of 247
Setting: 11 inpatient hospice or hospital palliative care services
Mean age years (SD): risperidone arm 74.5 years (10.6); haloperidol arm 76.5 years (8.2); placebo arm
73.8 (10.7) years
Gender no. female (%): risperidone 25 (31%); haloperidol 33 (41%); placebo 27 (32%)
Diagnosis (%): risperidone (93% cancer); haloperidol (83% cancer); placebo (89% cancer)
Delirium severity: baseline delirium severity assessed by the MDAS. Median and IQR scores were: 15.1
(5.8) in the risperidone arm; 14.6 (5.0) in the haloperidol arm; and 13.7 (4.8) in the placebo arm. Partici-
pants had mild- to moderate-severity delirium.
Performance status: Median Australian Karnofsky Performance Status scores were 40 (IQR 30 to 50) in
both the risperidone and placebo groups, and 50 (IQR 40 to 50) in the haloperidol group. AKPS scores
range from 0 (dead) to 100 (normal).
Inclusion criteria:
i) Adults receiving hospice or palliative care who required inpatient care from a specialist palliative care
team
ii) Delirium diagnosed via criteria from the DSM-IV (Fourth Edition,Text Revision)
iii) Memorial Delirium Assessment Scale (MDAS) score of 7 or more
iv) Presence of the target symptoms of delirium associated with distress
v) Able to speak English
Exclusion criteria:
Delirium due to substance withdrawal, history of neuroleptic malignant syndrome, regular use of an-
tipsychotic drugs within 48 hours, previous adverse reaction to antipsychotic drugs, extrapyramidal
disorders, prolonged QT interval, clinician-predicted survival of 7 days or fewer, cerebrovascular acci-
dent or seizure in the prior 30 days, and pregnancy or breastfeeding, unable to swallow.
Interventions Intervention 1: risperidone: oral risperidone solution 1 mg/4 ml. n = 82
Agar 2017 
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Intervention 2: haloperidol: oral haloperidol solution 1 mg/4 ml. n = 81
Comparison: placebo: oral placebo solution. n = 84
Participants 65 years or younger in the intervention groups received a 0.5 mg loading dose adminis-
tered with the first dose of 0.5 mg, then 0.5 mg maintenance doses every 12 hours. Doses could be
titrated by 0.25 mg on day 1 and by 0.5 mg thereafter to a maximum dose of 4 mg/d. For participants
older than 65 years, the loading, initial, and maximum doses were halved
The placebo solution was titrated similarly using matching volumes of solution for each dose level.
Doses were increased if the sum of NuDESC scores for items 2, 3, and 4 (delirium symptoms score) was
1 or more at the most recent assessment, conducted every 8 hours. Dose reduction to the prior dose
could occur for adverse effects, resolution of delirium (MDAS score of < 7 for 48 hours), or resolution of
symptoms (all NuDESC item scores < 1 for 48 hours)
Timing of treatment: maintenance dose every 12 hours after the baseline does (0 hours baseline, 12,
24, 36, 48, 60 hours)
Treatment duration: 72 hours
Outcomes Primary outcome:
• Delirium symptom scores were assessed by the Nu-DESC. Scores could range from 0 to 6, with higher
scores indicating more severe symptoms. The average of the last 2 delirium symptom scores on day
3 were used
Secondary outcomes:
• Delirium severity assessed daily by the MDAS score
• Lowest delirium symptoms score
• Daily use of midazolam
• Extrapyramidal symptoms assessed by the Extrapyramidal Symptom Rating Scale
• Sedation assessed by the Richmond Agitation-Sedation Scale
• Adverse events assessed by the National Cancer Institute Common Terminology Criteria for Adverse
Events
• Survival
Notes Study funder: Australian Government’s Department of Health under the National Palliative Care Strat-
egy. Individual site funding was supplemented by grant NHMRC 480476 from the National Health and
Medical Research Council, Australia
Conflicts of interest disclosure: none reported
Trial registration: ACTRN12607000562471
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Site randomisation schedules were generated using random number tables at
an independent blinded central registry
Allocation concealment
(selection bias)
Low risk Allocation concealment was by sealed opaque envelopes. Site clinical trial
pharmacists who opened the treatment schedules to prepare the intervention
were not otherwise involved in patient care. Study medication was dispensed
in opaque screw-top bottles, which were identical in terms of volume, colour,




Low risk Treatment assignment was double-blinded: both participants and investiga-
tors were masked to treatment group for the duration of the study
Agar 2017  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Treatment allocation will not be disclosed to patient and their proxy,




High risk Full details on attrition and exclusions are reported. The proportion of missing
data varied across trial arms. Dropout was higher in risperidone group (52%)
than in haloperidol group (37%) and the placebo group (35%). Dropout rates
could be different because of impact of intervention
Selective reporting (re-
porting bias)
Low risk Protocol available. The primary outcome and secondary outcomes were speci-
fied in the protocol




Methods Randomised clinical trial, single-site, double-blind, parallel groups, dose-titrated
Study duration: unclear but at least 7 days
Location: USA
Participants Total: 244 patients consented to participation and were monitored prospectively for the development
of delirium. 30 patients became delirious and were randomised.
Setting: hospital
Mean age years (SD): 39.2 years (SD = 8.8)
Gender no. (%): 23 male (77%), 7 female (23%)
Diagnosis (%): all patients had AIDS
Delirium severity: baseline delirium severity was assessed by the Delirium Rating Scale (DRS). Mean
scores were: 20.45 (SD = 3.45) in the haloperidol arm; 20.62 (SD = 3.88) in the chlorpromazine arm; and
18.33 (SD = 2.58) in the lorazepam arm
Performance status: mean Karnofsky Performance Status (KPS) across all participants was 52.3 (SD
= 21.3, range: 10 to 90), with no difference across treatment groups. KPS scores range from 0 (dead) to
100 (normal).
Inclusion criteria: patients with AIDS, ability to consent, medically stable, met DSM-III-R criteria for
delirium, score of 13 or greater on the DRS
Exclusion criteria: hypersensitivity to neuroleptics or benzodiazepines; presence of neuroleptic ma-
lignant syndrome; concurrent treatment with neuroleptic drugs; seizure disorder; current systemic
chemotherapy for Kaposi's sarcoma; withdrawal syndrome or anticholinergic delirium for which a
more specific treatment was indicated; diagnosis of schizophrenia; schizoaffective disorder or bipolar
disorder; patients in whom delirium appeared to be part of a terminal event (i.e. patient was expected
to die within 24 hours)
Interventions Intervention 1: haloperidol; mean dose during the first 24 hours: 2.8 mg (SD 2.4), average maintenance
dose from day 2 to end of treatment 1.4 mg (SD 1.2), n = 11
Intervention 2: chlorpromazine; mean doses during the first 24 hours: 50 mg (SD 23.1), average main-
tenance dose from day 2 to end of treatment 36 mg (SD 18.4), n = 13
Breitbart 1996 
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Intervention 3: lorazepam; mean doses during the first 24 hours: 3 mg (SD 4.7), average maintenance
dose from day 2 to end of treatment 4.6 mg (SD 4.7), n = 6
Assessment every hour in first 24 hours until participant was stabilised (calm, sleeping and not deliri-
ous).
Lorazepam arm stopped midway through study early due to adverse effects
Timing of treatment: each participant was evaluated hourly in first 24 hours with the DRS and the Ex-
trapyramindal Rating Scale. At the end of each hour, if the participant's score was still 13 or greater on
the DRS, the next level dose was administered. After stabilization, a maintenance dose was started on
day 2, and continued for up to 6 days of treatment protocol
Treatment duration: 7 days
Outcomes Outcomes (primary and secondary outcomes undifferentiated):
• Delirium symptoms assessed by the DRS
• Change in cognitive status assessed by the Mini-Mental State scores
• Extrapyramidal effects assessed by the Extrapyramidal Symptom Rating Scale ‒ a subjective ques-
tionnaire relating to parkinsonian symptoms
• Other adverse effects, assessed by the Side effects and Symptoms Checklist
Notes Funded by the National Institute of Mental Health grant MH-45664.
No information on conflicts of interest provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients meeting criteria for delirium were randomised by the hospi-
tal pharmacy and treated in a double-blind fashion with one of the three study
drugs". Comment: no information provided on how patients were randomised
Allocation concealment
(selection bias)





Low risk Double blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Unclear risk No information on extent of missing data or how it was handled. No informa-
tion on which scores were averaged to obtain average delirium rating scale
scores on day 2. In all trial arms participants died during treatment (2 chlor-
promazine, 2 haloperidol, 1 lorazepam). Lorazepam arm terminated early




Unclear risk Protocol not available. Insufficient information to judge selective reporting
bias.
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Methods Randomised clinical trial, single-site, placebo-controlled, double-blind, parallel groups
Study duration: from baseline assessment until discharge or death
Location: USA
Participants Total: 90 patients randomised and started on standardised haloperidol regimen. 58 developed an agi-
tation episode and received study medication
Setting: acute palliative care unit in a cancer centre
Mean age years (range): lorazepam plus haloperidol 66 years (43 to 90); placebo plus haloperidol 64
years (30 to 88)
Gender no. (% female): lorazepam plus haloperidol 11 (38%); placebo plus haloperidol 16 (55%)
Diagnosis (%): 100% cancer
Delirium severity: baseline delirium severity was assessed by the Memorial Delirium Assessment Scale
(MDAS). Scores can range from 0 to 30 with higher scores indicating greater severity. Median and IQR
scores were: 30.0 (23.0 to 30) in the lorazepam and haloperidol group; and 28.0 (19.0 to 30.0) in the
placebo and haloperidol group. Participants had moderate to severe delirium.
Performance status: 89.6% of participants in the lorazepam and haloperidol group, and 93% in the
placebo and haloperidol group had Karnofsky Performance Status (KPS) scores of 30 or lower and were
considered severely disabled and in need to hospitalisation. KPS scores range from 0 (dead) to 100
(normal)
Inclusion criteria: adult patients who were 18 years or older with a diagnosis of advanced cancer. All
had a diagnosis of delirium using DSM-IV-TR criteria; and a history of agitation with a Richmond Agita-
tion-Sedation Scale (RASS) score of 1 or more over the previous 24 hours despite receiving scheduled
haloperidol of 1 mg to 8 mg per day. Between February 2014 and August 2014 study medication was
started as a form of rescue medication for agitation, if RASS score was 2 or more. In September 2014,
the RASS score threshold was reduced to 1 or more to allow any patient with agitation proceed to the
blinded phase.
Exclusion criteria: dementia, use of benzodiazepines or chlorpromazine within the previous 48 hours;
contraindications to neuroleptics or contraindications to benzodiazepines
Interventions Intervention: lorazepam plus haloperidol. n = 29
Enrolled patients were immediately started on a standardised open-label regimen of haloperidol (2
mg) every 4 hours intravenously. If they met the need for rescue medication for agitation they were
randomised to receive either of the study medications. In the intervention arm, once the participant
met the agitation threshold for rescue medication, a single dose of 3 mg of lorazepam in 25 ml of 0.9%
normal saline solution was infused intravenously over 1.5 minutes
Comparison: placebo plus haloperidol. n = 29
Once the participant met the threshold for rescue medication, a single dose of identically appearing
placebo was infused intravenously over 1.5 minutes
Timing of treatment: medication was administered once the participant reached the threshold for res-
cue medication based on their RASS score (RASS threshold was 1 or more)
Treatment duration: single administration
Outcomes Primary outcome:
• Change in agitation as assessed by RASS score change from baseline to 8 hours after study medication
administration. The RASS score is 10-point numeric rating scale that ranges from −5 (unarousable) to
4 (very agitated or combative)
Hui 2017 
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Secondary outcomes:
• Delirium severity assessed by the MDAS
• Use of additional rescue agents
• Palliative symptoms assessed by the Edmonton Symptom Assessment System
• Comfort (perceived by caregivers and nurses)
• Delirium recall
• Communication capacity
• Adverse effects assessed using the Udvalg for Kliniske Undersøgelser (UKU) assessment
• Discharge outcomes
• Overall survival
Notes Study funder: this study was supported by grant R21CA186000-01A1 from the National Cancer Institute
(Drs Hui, Bruera, Hess, and Breitbart); a Mentored Research Scholar Grant in Applied and Clinical Re-
search (MRSG-14-1418-01-CCE) from the American Cancer Society (Dr Hui) and the Andrew Sabin Fam-
ily Fellowship Award (Dr Hui) from the Andrew Sabin Family Foundation; grant P30CA016672 from the
National Institutes of Health Cancer Center (Drs Diba and Hess and Ms Liu); and grant R01CA200867
from the National Institutes of Health (Dr Delgado-Guay)
Conflicts of interest disclosure: none reported
Trial registration – ClinicalTrials.gov Identifier: NCT01949662
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Allocation was concealed by using a secured website that was only accessible





Low risk Research staE conducting the study assessments, bedside nurses, attending
physicians, patients,and caregivers were blinded to the allocation of the study
medication and study outcomes throughout the entire study.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Blinded physicians and nurses were involved in the identification of






Low risk Reasons for attrition are described. 3 participants lost to follow-up in both the
intervention and comparison groups. In the intervention group 1 died and 2
were discharged; in the comparison group 3 died.
Selective reporting (re-
porting bias)
Low risk Protocol available; primary and secondary outcomes reported correspond
with those identified in the protocol.




Methods Randomized clinical trial, single-site, open trial, parallel groups
Lin 2008 
Drug therapy for delirium in terminally ill adults (Review)









Cochrane Database of Systematic Reviews
Study duration: 1 week from baseline assessment
Location: Taiwan
Participants Total: 30 patients
Setting: hospice and palliative care centre at a large general and teaching hospital
Mean age years (SD): olanzapine 61 years (16.50); haloperidol 68 years (12.14)
Gender no. (% female): olanzapine 7 (44%); haloperidol 10 (71%)
Diagnosis (%): 100% cancer
Delirium severity: baseline delirium severity was assessed by the Delirium Rating Scale (Chinese ver-
sion). DRS (Chinese) scores could range from 10 to 33 with higher scores indicating greater severity.
Mean and standard deviations scores were: 17.56 (SD = 5.18) in the olanzapine group and 16.50 (SD =
4.70) in the haloperidol group
Performance status: not assessed.
Inclusion criteria: patients with advanced cancer requiring hospice and palliative care; diagnosis of
delirium as per the DSM-IV
Exclusion criteria: past history of psychiatric disorders; coma, inability to swallow oral medication,
treatment with neuroleptic agents within 4 weeks prior to the enrolment
Interventions Intervention: olanzapine starting dose 5 mg per day ‒ oral. n = 16
Comparison: haloperidol starting dose 5 mg per day ‒ oral. n = 14
If the participant's condition did not improve doses were titrated up to a maximum daily dose of 15
mg olanzapine or 15 mg haloperidol. Midazolam by intramuscular injection was available when rescue
medication was required
Timing of treatment: commenced at 6 p.m. on day 1 with doses administered every 24 hours
Treatment duration: 1 week
Outcomes Outcomes (primary and secondary outcomes undifferentiated):
• Delirium severity assessed by the Chinese version of the Delirium Rating Scale (DRS-c). Scores ranged
from 0 to 33 (in contrast to 0 to 32 for the English DRS).
• Treatment response assessed by the Clinical Global Impression Severity (CGI-S) scale. The CGI is a 3-
item scale used to assess treatment response in psychiatric patients ‒ severity of illness, global im-
provement, and efficacy index. The CGI-S is one of CGI items assessing illness severity with scores
ranging from 1 (normal) to 7 (extremely ill).
Notes No information on funding or conflicts of interest provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "If the patients needed to have antipsychotic, they were separated ran-
domly to an olanzapine group or a haloperidol group"
Comment: no information provided on how participants were randomised
Allocation concealment
(selection bias)
Unclear risk No information provided
Lin 2008  (Continued)
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High risk Incomplete blinding ‒ assessor was blinded to the treatment received by each
participant but participants were unblinded. However, participant unblinding
is unlikely to have an effect on the outcome
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "The assessor was blind to what kind of antipsychotic the patients re-
ceived when she assessed the following DRS-C and CGI-S and the side effect of




High risk High rates of dropout. 11/16 (67%) dropped out in the olanzapine group and
7/14 (50%) dropped out in the haloperidol group. No reasons given and no in-




Unclear risk Protocol not available. Insufficient information to judge selective reporting
bias
Sample size High risk Fewer than 50 participants per arm
Lin 2008  (Continued)
DRS: Delirium Rating Scale
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders III (revision)
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders III (revision)
IQR: Interquartile range
mg: milligram
mg/d: milligrams per day
ml: millilitre
MMSE: Mini-Mental State Examination
n: Sample size
QT interval: measurement made on an electrocardiogram used to assess some of the electrical properties of the heart. It is calculated as
the time from the start of the Q wave to the end of the T wave and approximates to the time taken from when the cardiac ventricles start
to contract to when they finish relaxing.
SD: standard deviation
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ather 1986 No validated diagnosis of delirium
Auchus 1997 No validated diagnosis of delirium
Boettger 2011a Not a randomised controlled trial
Boettger 2011b Not a randomised controlled trial
Boettger 2015 Not a randomised controlled trial
Breitbart 2002 Not a randomised controlled trial
Clayton-Chubb 2016 Participants were not terminally ill
Djokic 2008 Participants were not terminally ill
Ferraz Gonçalves 2016a Not a randomised controlled trial - place randomised only
Grover 2011 Participants were not terminally ill
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Study Reason for exclusion
Han 2004 Participants were not terminally ill
Han 2010 Not a randomised controlled trial
Hu 2006 Participants were not terminally ill
Kim 2010 Participants were not terminally ill
Kim 2014 Not a randomised controlled trial
Lee 2005 Participants were not terminally ill
Lee 2007 Participants were not terminally ill
Lee 2013 Participants were not terminally ill
Mittal 2004 Not a randomised controlled trial
Miyaji 2007 Not a randomised controlled trial
Moretti 2004 Participants were not terminally ill; does not report outcomes of interest
Naber 2007 Participants were not terminally ill
Overshott 2010 Participants were not terminally ill
Parellada 2004 Participants were not terminally ill
Pelosi 2008 No validated diagnosis of delirium
Perkisas 2015 Focus on delirium prevention as opposed to treatment
Sakong 2010 Participants were not terminally ill
Sasaki 2003 Not a randomised controlled trial
Sipahimalani 1998 Participants were not terminally ill
Tahir 2009 Participants were not terminally ill
Tahir 2010 Participants were not terminally ill
Tanimukai 2016 Participants were not terminally ill
van der Vorst 2018 Conference abstract only
van Eijk 2010 Participants were not terminally ill
Yang 2012 Does not focus on drug therapy for delirium treatment. Focus is on bright light therapy
Yoon 2013 Participants were not terminally ill
Zaslavsky 2012 Participants were not terminally ill
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Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised controlled trial
Participants Hospitalised patients with advanced cancer diagnosed with delirium (DSM-IV-TR)
100 participants randomised between January 2011 and June 2016
Olanzapine (n = 50); haloperidol (n = 50)
Interventions Olanzapine versus haloperidol
Outcomes Primary outcome:
Delirium response rate (DRR) defined as the Delirium Rating Scale-Revised-98 (DRS-R-98) total




Delirium-related distress (assessed by the Delirium Experience Questionnaire)
Notes Responsible party: H.M.W. Verheul, VU University Medical Center.
ClinicalTrials.gov identifier: NCT01539733
Conference abstract published: van der Vorst 2018.
Full paper unpublished at time of search (8 July 2019), but subsequently published on 4 December
2019 (van der Vorst 2019)
van der Vorst 2019 
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Haloperidol and/or chlorpromazine for refractory agitated delirium
Methods Randomised controlled trial
Participants 54 participants with advanced cancer admitted to an acute palliative care unit.
• Delirium according to DSM-V criteria for hyperactive or mixed delirium with Richmond Agita-
tion-Sedation Scale (RASS) ≥ 1 in the past 24 hours
Interventions All participants receive haloperidol 2 mg intravenously every 6 hours regularly and every hour as
needed upon admission to acute palliative care unit (APCU). If RASS scores reach ≥ +2, participant
randomised
Group1: haloperidol only ‒ haloperidol 2 mg intravenously every 4 hours and every hour as needed
Group 2: chlorpromazine only ‒ chlorpromazine 25 mg intravenously every 4 hours and every hour
as needed
Group 3: haloperidol and chlorpromazine ‒ haloperidol 1 mg intravenously every 4 hours and every
hour as needed
NCT03021486 
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Outcomes Primary outcome:
Agitation intensity in participants admitted to an acute palliative care unit who did not experience
a response to low-dose haloperidol (time frame: 24 hours). Agitation intensity is being measured by
Richmond Agitation-Sedation Scale (RASS)
Starting date 5 June 2017
Estimated study completion date: June 2021
Contact information Responsible Party: M.D. Anderson Cancer Center






Trial name or title Haloperidol and lorazepam in controlling symptoms of persistent agitated delirium in patients
with advanced cancer undergoing palliative care
Methods Randomised controlled trial
Participants 206 participants with advanced cancer admitted to an acute palliative care unit
• With hyperactive or mixed delirium with RASS ≥ 1 in the past 24 hours despite efforts to treat po-
tential underlying cause
Interventions Group 1: participants receive haloperidol IV over 3 to 15 minutes every 4 hours and as needed and
placebo IV every 4 hours and as needed until discharge from palliative care unit.
Group 2: participants receive lorazepam IV over 3 to 15 minutes every 4 hours and as needed and
placebo IV every 4 hours and as needed until discharge from palliative care unit.
Group 3: participants receive haloperidol IV over 3 to 15 minutes every 4 hours and as needed and
lorazepam IV over 3 to 15 minutes every 4 hours and as needed until discharge from palliative care
unit
Group 4: patients receive placebo IV every 4 hours and lorazepam IV over 3 to 15 minutes as needed
until discharge from palliative care unit.
Outcomes Primary outcome:
Change in Richmond Agitation Sedation Scale (RASS) score in patients admitted to an acute pallia-
tive care unit (time frame: baseline to 24 hours)
Secondary outcomes:
Rescue medication use at 24 hours
Proportion of patients in the target RASS range (defined as RASS between −2 and 0) as well as the
proportion of patients achieving treatment response (defined as RASS reduction of ≥ 1.5 points) at
24 hours
Perceived comfort as assessed by caregivers and bedside nurses at 24 hours
Proxy comfort goal up to 24 hours
NCT03743649 
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Symptom expression assessed using Edmonton Symptom Assessment Scale at 24 hours
Delirium severity assessed using Memorial Delirium Assessment Scale at 24 hours
Incidence of adverse events up to 24 hours
Quality of end-of-life care at 24 hours
Novel predictive markers of response up to 24 hours
Starting date 31 May 2019
Contact information Responsible Party: M.D. Anderson Cancer Center




DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision






D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Delirium symptoms within 24 hours of start of intervention





Statistical method Effect size
1 Haloperidol versus placebo 1 133 Mean Difference (IV, Fixed, 95% CI) 0.34 [-0.07, 0.75]
2 Haloperidol versus risperidone 1 126 Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.90, 0.06]
3 Haloperidol versus olanzapine 1 28 Mean Difference (IV, Fixed, 95% CI) 2.36 [-0.75, 5.47]
4 Risperidone versus placebo 1 129 Mean Difference (IV, Fixed, 95% CI) 0.76 [0.30, 1.22]
5 Lorazepam as an adjunct to haloperi-
dol versus placebo as an adjunct to
haloperidol
    Other data No numeric data
 
 
Analysis 1.1.   Comparison 1 Delirium symptoms within 24 hours
of start of intervention, Outcome 1 Haloperidol versus placebo.
Study or subgroup Haloperidol Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Agar 2017 65 1.3 (1.3) 68 1 (1.2) 100% 0.34[-0.07,0.75]
Favours haloperidol 10.5-1 -0.5 0 Favours placebo
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Study or subgroup Haloperidol Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
   
Total *** 65   68   100% 0.34[-0.07,0.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.62(P=0.11)  
Favours haloperidol 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Delirium symptoms within 24 hours of
start of intervention, Outcome 2 Haloperidol versus risperidone.
Study or subgroup Haloperidol Risperidone Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Agar 2017 65 1.3 (1.3) 61 1.7 (1.5) 100% -0.42[-0.9,0.06]
   
Total *** 65   61   100% -0.42[-0.9,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.71(P=0.09)  
Favours Haloperidol 10050-100 -50 0 Favours Risperidone
 
 
Analysis 1.3.   Comparison 1 Delirium symptoms within 24 hours
of start of intervention, Outcome 3 Haloperidol versus olanzapine.
Study or subgroup Olanzapine Haloperidol Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Lin 2008 14 14.3 (4.6) 14 11.9 (3.8) 100% 2.36[-0.75,5.47]
   
Total *** 14   14   100% 2.36[-0.75,5.47]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.49(P=0.14)  
Favours olanzapine 10050-100 -50 0 Favours haloperidol
 
 
Analysis 1.4.   Comparison 1 Delirium symptoms within 24 hours
of start of intervention, Outcome 4 Risperidone versus placebo.
Study or subgroup Risperidone Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Agar 2017 61 1.7 (1.5) 68 1 (1.2) 100% 0.76[0.3,1.22]
   
Total *** 61   68   100% 0.76[0.3,1.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.24(P=0)  
Favours risperidone 21-2 -1 0 Favours placebo
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Analysis 1.5.   Comparison 1 Delirium symptoms within 24 hours of start of intervention,
Outcome 5 Lorazepam as an adjunct to haloperidol versus placebo as an adjunct to haloperidol.
Lorazepam as an adjunct to haloperidol versus placebo as an adjunct to haloperidol
Study  
Hui 2017 MD 2.10, 95% CI -1.00 to 5.20
 
 
Comparison 2.   Delirium symptoms between 24 and 48 hours of start of intervention





Statistical method Effect size
1 Haloperidol versus placebo 1 123 Mean Difference (IV, Fixed, 95%
CI)
0.49 [0.10, 0.88]
2 Haloperidol versus risperidone 1 106 Mean Difference (IV, Fixed, 95%
CI)
-0.36 [-0.92, 0.20]
3 Haloperidol versus olanzapine 1 24 Mean Difference (IV, Fixed, 95%
CI)
1.90 [-1.50, 5.30]
4 Risperidone versus placebo 1 111 Mean Difference (IV, Fixed, 95%
CI)
0.85 [0.32, 1.38]
5 Haloperidol versus chlorpromazine 1 24 Mean Difference (IV, Fixed, 95%
CI)
0.37 [-4.58, 5.32]
6 Haloperidol versus lorazepam 1 17 Mean Difference (IV, Fixed, 95%
CI)
-4.88 [-9.70, -0.06]





Analysis 2.1.   Comparison 2 Delirium symptoms between 24 and 48
hours of start of intervention, Outcome 1 Haloperidol versus placebo.
Study or subgroup Haloperidol Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Agar 2017 59 1.2 (1.2) 64 0.7 (1) 100% 0.49[0.1,0.88]
   
Total *** 59   64   100% 0.49[0.1,0.88]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.47(P=0.01)  
Favours haloperidol 21-2 -1 0 Favours placebo
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Analysis 2.2.   Comparison 2 Delirium symptoms between 24 and 48
hours of start of intervention, Outcome 2 Haloperidol versus risperidone.
Study or subgroup Haloperidol Risperidone Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Agar 2017 59 1.2 (1.2) 47 1.6 (1.7) 100% -0.36[-0.92,0.2]
   
Total *** 59   47   100% -0.36[-0.92,0.2]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
Favours haloperidol 10050-100 -50 0 Favours risperidone
 
 
Analysis 2.3.   Comparison 2 Delirium symptoms between 24 and 48
hours of start of intervention, Outcome 3 Haloperidol versus olanzapine.
Study or subgroup Olanzapine Haloperidol Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Lin 2008 10 14.9 (3.5) 14 13 (5) 100% 1.9[-1.5,5.3]
   
Total *** 10   14   100% 1.9[-1.5,5.3]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.09(P=0.27)  
Favours [Olanzapine] 10050-100 -50 0 Favours [Haloperidol]
 
 
Analysis 2.4.   Comparison 2 Delirium symptoms between 24 and 48
hours of start of intervention, Outcome 4 Risperidone versus placebo.
Study or subgroup Risperidone Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Agar 2017 47 1.6 (1.7) 64 0.7 (1) 100% 0.85[0.32,1.38]
   
Total *** 47   64   100% 0.85[0.32,1.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.13(P=0)  
Risperidone 10050-100 -50 0 Placebo
 
 
Analysis 2.5.   Comparison 2 Delirium symptoms between 24 and 48 hours
of start of intervention, Outcome 5 Haloperidol versus chlorpromazine.
Study or subgroup Haloperidol Chlorpromazine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 11 12.5 (5.9) 13 12.1 (6.5) 100% 0.37[-4.58,5.32]
   
Total *** 11   13   100% 0.37[-4.58,5.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours haloperidol 10050-100 -50 0 Favours chlorpromazine
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Analysis 2.6.   Comparison 2 Delirium symptoms between 24 and 48
hours of start of intervention, Outcome 6 Haloperidol versus lorazepam.
Study or subgroup Haloperidol Lorazepam Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 11 12.5 (5.9) 6 17.3 (4.2) 100% -4.88[-9.7,-0.06]
   
Total *** 11   6   100% -4.88[-9.7,-0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.98(P=0.05)  
Favours haloperidol 10050-100 -50 0 Favours lorazepam
 
 
Analysis 2.7.   Comparison 2 Delirium symptoms between 24 and 48 hours
of start of intervention, Outcome 7 Lorazepam versus chlorpromazine.
Study or subgroup Lorazepam Chlorpromazine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 6 17.3 (4.2) 13 12.1 (6.5) 100% 5.25[0.38,10.12]
   
Total *** 6   13   100% 5.25[0.38,10.12]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.11(P=0.03)  
Favours lorazepam 10050-100 -50 0 Favours chlorpromazine
 
 
Comparison 3.   Agitation within 24 hours of start of intervention








1 Lorazepam as an adjunct to haloperidol versus placebo as an ad-
junct to haloperidol




Analysis 3.1.   Comparison 3 Agitation within 24 hours of start of intervention, Outcome
1 Lorazepam as an adjunct to haloperidol versus placebo as an adjunct to haloperidol.
Lorazepam as an adjunct to haloperidol versus placebo as an adjunct to haloperidol
Study  
Hui 2017 MD 1.9, 95% CI 0.9 to 2.8
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Comparison 4.   Agitation between 24 and 48 hours of the start of the intervention





Statistical method Effect size
1 Haloperidol versus placebo     Other data No numeric data
2 Risperidone versus placebo     Other data No numeric data
 
 
Analysis 4.1.   Comparison 4 Agitation between 24 and 48 hours of
the start of the intervention, Outcome 1 Haloperidol versus placebo.
Haloperidol versus placebo
Study  
Agar 2017 MD -0.14, 95% CI -0.28 to -0.00
 
 
Analysis 4.2.   Comparison 4 Agitation between 24 and 48 hours of
the start of the intervention, Outcome 2 Risperidone versus placebo.
Risperidone versus placebo
Study  
Agar 2017 MD -0.05, 95% CI -0.19 to 0.09
 
 
Comparison 5.   Number of adverse events





Statistical method Effect size
1 Haloperidol versus placebo (extrapyramidal adverse
effects)
    Other data No numeric data
2 Lorazepam as an adjunct to haloperidol versus place-
bo as an adjunct to haloperidol (adverse events hypoki-
nesia or akinesia)
1 31 Risk Ratio (M-H, Fixed,
95% CI)
0.70 [0.19, 2.63]
3 Risperidone versus placebo (extrapyramidal adverse
effects)
    Other data No numeric data
4 Haloperidol versus chlorpromazine (extrapyramidal
adverse effects)
1 24 Mean Difference (IV, Fixed,
95% CI)
0.46 [-4.22, 5.14]
5 Haloperidol versus lorazepam (adverse events of hy-
pokinesia or akinesia)
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Analysis 5.1.   Comparison 5 Number of adverse events, Outcome
1 Haloperidol versus placebo (extrapyramidal adverse eDects).
Haloperidol versus placebo (extrapyramidal adverse effects)
Study  
Agar 2017 MD 0.79, 95% CI 0.17 to 1.41
 
 
Analysis 5.2.   Comparison 5 Number of adverse events, Outcome 2 Lorazepam as an adjunct to
haloperidol versus placebo as an adjunct to haloperidol (adverse events hypokinesia or akinesia).
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hui 2017 3/16 4/15 100% 0.7[0.19,2.63]
   
Total (95% CI) 16 15 100% 0.7[0.19,2.63]
Total events: 3 (Experimental), 4 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.52(P=0.6)  
Favours [Lorazepam] 1000.01 100.1 1 Favours [Placebo]
 
 
Analysis 5.3.   Comparison 5 Number of adverse events, Outcome
3 Risperidone versus placebo (extrapyramidal adverse eDects).
Risperidone versus placebo (extrapyramidal adverse effects)
Study  
Agar 2017 MD 0.73, 95% CI 0.09 to 1.37
 
 
Analysis 5.4.   Comparison 5 Number of adverse events, Outcome 4
Haloperidol versus chlorpromazine (extrapyramidal adverse eDects).
Study or subgroup Haloperidol Chlorpromazine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 11 5.5 (6.8) 13 5.1 (4.5) 100% 0.46[-4.22,5.14]
   
Total *** 11   13   100% 0.46[-4.22,5.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Favours haloperidol 105-10 -5 0 Favours chlorpromazine
 
 
Analysis 5.5.   Comparison 5 Number of adverse events, Outcome 5
Haloperidol versus lorazepam (adverse events of hypokinesia or akinesia).
Study or subgroup Haloperidol Lorazepam Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 11 5.5 (6.8) 6 12.2 (8.9) 100% -6.66[-14.85,1.53]
   
Favours haloperidol 10050-100 -50 0 Favours lorazepam
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Study or subgroup Haloperidol Lorazepam Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Total *** 11   6   100% -6.66[-14.85,1.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.59(P=0.11)  
Favours haloperidol 10050-100 -50 0 Favours lorazepam
 
 
Analysis 5.6.   Comparison 5 Number of adverse events, Outcome 6 Lorazepam versus chlorpromazine.
Study or subgroup Lorazepam Chlorpromazine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 5 12.2 (8.9) 13 5.1 (4.5) 100% 7.12[-1.08,15.32]
   
Total *** 5   13   100% 7.12[-1.08,15.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.7(P=0.09)  
Favours lorazepam 10050-100 -50 0 Favours chlorpromazine
 
 
Comparison 6.   Secondary outcomes





Statistical method Effect size
1 Use of rescue medication: Haloperidol or risperidone
versus placebo
1 189 Risk Ratio (M-H, Fixed,
95% CI)
2.04 [1.12, 3.71]
2 Use of rescue medication: Lorazepam as adjunct to
haloperidol versus placebo as an adjunct to haloperi-
dol
    Other data No numeric data
3 Cognitive status: Haloperidol versus chlorpromazine 1 24 Mean Difference (IV,
Fixed, 95% CI)
-1.04 [-8.83, 6.75]
4 Cognitive status: Haloperidol versus lorazepam 1 17 Mean Difference (IV,
Fixed, 95% CI)
4.6 [-5.12, 14.32]
5 Cognitive status: Lorazepam versus chlorpromazine 1 19 Mean Difference (IV,
Fixed, 95% CI)
-5.64 [-15.65, 4.37]
6 Survival: Haloperidol versus placebo     Other data No numeric data
7 Survival: Risperidone versus placebo     Other data No numeric data
8 Survival: Lorazepam as adjunct to haloperidol versus
placebo as an adjunct to haloperidol
    Other data No numeric data
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Analysis 6.1.   Comparison 6 Secondary outcomes, Outcome 1 Use
of rescue medication: Haloperidol or risperidone versus placebo.
Study or subgroup Haloperidol Risperidone Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Agar 2017 40/121 11/68 100% 2.04[1.12,3.71]
   
Total (95% CI) 121 68 100% 2.04[1.12,3.71]
Total events: 40 (Haloperidol), 11 (Risperidone)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.34(P=0.02)  
Favours haloperidol 1000.01 100.1 1 Favours risperidone
 
 
Analysis 6.2.   Comparison 6 Secondary outcomes, Outcome 2 Use of rescue medication:
Lorazepam as adjunct to haloperidol versus placebo as an adjunct to haloperidol.
Use of rescue medication: Lorazepam as adjunct to haloperidol versus placebo as an adjunct to haloperidol
Study  
Hui 2017 Median difference -1.0 mg, 95% CI -2.00 to 0.00
 
 
Analysis 6.3.   Comparison 6 Secondary outcomes, Outcome 3 Cognitive status: Haloperidol versus chlorpromazine.
Study or subgroup Haloperidol Chlorpromazine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 11 17.3 (8.9) 13 18.3 (10.6) 100% -1.04[-8.83,6.75]
   
Total *** 11   13   100% -1.04[-8.83,6.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.79)  
Favours haloperidol 10050-100 -50 0 Favours chlorpromazine
 
 
Analysis 6.4.   Comparison 6 Secondary outcomes, Outcome 4 Cognitive status: Haloperidol versus lorazepam.
Study or subgroup Haloperidol Lorazepam Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 11 17.3 (8.9) 6 12.7 (10.2) 100% 4.6[-5.12,14.32]
   
Total *** 11   6   100% 4.6[-5.12,14.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Favours haloperidol 10050-100 -50 0 Favours lorazepam
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Analysis 6.5.   Comparison 6 Secondary outcomes, Outcome 5 Cognitive status: Lorazepam versus chlorpromazine.
Study or subgroup Lorazepam Chlorpromazine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Breitbart 1996 6 12.7 (10.2) 13 18.3 (10.6) 100% -5.64[-15.65,4.37]
   
Total *** 6   13   100% -5.64[-15.65,4.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
Favours lorazepam 10050-100 -50 0 Favours chlorpromazine
 
 
Analysis 6.6.   Comparison 6 Secondary outcomes, Outcome 6 Survival: Haloperidol versus placebo.
Survival: Haloperidol versus placebo
Study  
Agar 2017 Hazard ratio 1.73, 95% CI 1.20 to 2.50
 
 
Analysis 6.7.   Comparison 6 Secondary outcomes, Outcome 7 Survival: Risperidone versus placebo.
Survival: Risperidone versus placebo
Study  
Agar 2017 Hazard ratio 1.29, 95% CI 0.91 to 1.84
 
 
Analysis 6.8.   Comparison 6 Secondary outcomes, Outcome 8 Survival:
Lorazepam as adjunct to haloperidol versus placebo as an adjunct to haloperidol.
Survival: Lorazepam as adjunct to haloperidol versus placebo as an adjunct to haloperidol
Study  
Hui 2017 HR 1.20, 95% CI 0.70 to 2.20
 
 
A P P E N D I C E S
Appendix 1. Search Strategies
CENTRAL (CRSO)
#1 MESH DESCRIPTOR Delirium
#2 ((delirum or delirious)):TI,AB,KY
#3 MESH DESCRIPTOR Psychomotor Agitation
#4 agitat*:TI,AB,KY
#5 ((distress or distressed)):TI,AB,KY
#6 restless*:TI,AB,KY
#7 (((disturbed or disordered or abnormal* or change*) adj2 (attention or cognition or cognitive or consciousness or perception))):TI,AB,KY
#8 ("acute brain syndrome"):TI,AB,KY
#9 ("acute cerebral insuEiciency"):TI,AB,KY
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#10 ("acute confusion"):TI,AB,KY
#11 ("acute confusional state"):TI,AB,KY
#12 MESH DESCRIPTOR Cognitive Dysfunction
#13 ((cognitive adj2 (dysfunction or decline))):TI,AB,KY
#14 ((mental* adj2 deterioration)):TI,AB,KY
#15 MESH DESCRIPTOR Consciousness Disorders
#16 ((diminish* adj2 consciousness)):TI,AB,KY
#17 MESH DESCRIPTOR Brain Diseases
#18 encephalopathy:TI,AB,KY
#19 ((fail* adj2 cognit*)):TI,AB,KY
#20 MESH DESCRIPTOR Neurocognitive Disorders
#21 (organic mental disorder):TI,AB,KY
#22 ("acute organic psychosyndrome*"):TI,AB,KY
#23 ("acute psycho-organic syndrome*"):TI,AB,KY
#24 ("exogenous psychosis"):TI,AB,KY
#25 (clouded state):TI,AB,KY
#26 ((Cloud* adj2 conscious*)):TI,AB,KY
#27 MESH DESCRIPTOR Brain Diseases, Metabolic
#28 ((metabolic adj2 encephalopathy)):TI,AB,KY
#29 ((disturbance adj2 brain function)):TI,AB,KY
#30 (toxic psychosis):TI,AB,KY
#31 (toxic confusion):TI,AB,KY
#32 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
#33 MESH DESCRIPTOR Alprazolam
#34 Alprazolam:TI,AB,KY
#35 Amisulpride:TI,AB,KY
#36 MESH DESCRIPTOR Amobarbital
#37 Amobarbital:TI,AB,KY
#38 MESH DESCRIPTOR Aripiprazole
#39 Aripiprazole:TI,AB,KY
#40 MESH DESCRIPTOR Benperidol
#41 Benperidol:TI,AB,KY
#42 MESH DESCRIPTOR Bromazepam
#43 Bromazepam:TI,AB,KY
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#44 MESH DESCRIPTOR Clorazepate Dipotassium
#45 Chlorazepate:TI,AB,KY
#46 Chlordiazepam:TI,AB,KY
#47 MESH DESCRIPTOR Chlordiazepoxide
#48 Chlordiazepoxide:TI,AB,KY
#49 MESH DESCRIPTOR Chlorpromazine
#50 Chlorpromazine:TI,AB,KY
#51 MESH DESCRIPTOR Cytidine Diphosphate Choline
#52 Citicoline:TI,AB,KY
#53 Clobazam:TI,AB,KY
#54 MESH DESCRIPTOR Clonazepam
#55 MESH DESCRIPTOR Clonidine
#56 Clonidine:TI,AB,KY
#57 MESH DESCRIPTOR Clozapine
#58 Clozapine:TI,AB,KY
#59 Desmethylalprazolam:TI,AB,KY
#60 MESH DESCRIPTOR Dextroamphetamine
#61 Dexamphetamine:TI,AB,KY
#62 MESH DESCRIPTOR Dexmedetomidine
#63 Dexmedetomidine:TI,AB,KY




#68 MESH DESCRIPTOR Droperidol
#69 Droperidol:TI,AB,KY
#70 MESH DESCRIPTOR Estazolam
#71 Estazolam:TI,AB,KY
#72 MESH DESCRIPTOR Flumazenil
#73 Flumazepil:TI,AB,KY
#74 Flumazenil:TI,AB,KY
#75 MESH DESCRIPTOR Flunitrazepam
#76 Flunitrazepam:TI,AB,KY
#77 MESH DESCRIPTOR Flupenthixol
#78 Flupenthixol:TI,AB,KY
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#79 MESH DESCRIPTOR Flupenthixol
#80 Flupentixol:TI,AB,KY
#81 MESH DESCRIPTOR Fluphenazine
#82 Fluphenazine:TI,AB,KY
#83 MESH DESCRIPTOR Flurazepam
#84 Flurazepam:TI,AB,KY
#85 Gabapentin:TI,AB,KY
#86 MESH DESCRIPTOR Galantamine
#87 Galantamine:TI,AB,KY
#88 Halazepam:TI,AB,KY




#93 MESH DESCRIPTOR Methotrimeprazine
#94 Levomepromazine:TI,AB,KY




#99 MESH DESCRIPTOR Melatonin
#100 Melatonin:TI,AB,KY
#101 MESH DESCRIPTOR Mesoridazine
#102 Mesoridazine:TI,AB,KY
#103 MESH DESCRIPTOR Methotrimeprazine
#104 Methotrimeprazine:TI,AB,KY
#105 MESH DESCRIPTOR Methylphenidate
#106 Methylphenidate:TI,AB,KY
#107 MESH DESCRIPTOR Midazolam
#108 Midazolam:TI,AB,KY
#109 Modafinil:TI,AB,KY
#110 MESH DESCRIPTOR Nitrazepam
#111 Nitrazepam:TI,AB,KY
#112 MESH DESCRIPTOR Nitrous Oxide
#113 (Nitrous oxide):TI,AB,KY
Drug therapy for delirium in terminally ill adults (Review)









Cochrane Database of Systematic Reviews
#114 Olanzapine:TI,AB,KY
#115 Orap:TI,AB,KY
#116 MESH DESCRIPTOR Oxazepam
#117 Oxazepam:TI,AB,KY




#122 MESH DESCRIPTOR Perphenazine
#123 Perphenazine:TI,AB,KY




#128 MESH DESCRIPTOR Pimozide
#129 Pimozide:TI,AB,KY
#130 Pipotiazine:TI,AB,KY
#131 MESH DESCRIPTOR Prazepam
#132 Prazepam:TI,AB,KY
#133 MESH DESCRIPTOR Pregabalin
#134 Pregabalin:TI,AB,KY
#135 MESH DESCRIPTOR Prochlorperazine
#136 Prochlorperazine:TI,AB,KY
#137 MESH DESCRIPTOR Promazine
#138 Promazine:TI,AB,KY
#139 MESH DESCRIPTOR Promethazine
#140 Promethazine:TI,AB,KY





#146 MESH DESCRIPTOR Risperidone
#147 Risperidone:TI,AB,KY
#148 MESH DESCRIPTOR Rivastigmine
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#153 MESH DESCRIPTOR Sufentanil
#154 Sufentanil:TI,AB,KY
#155 MESH DESCRIPTOR Sulpiride
#156 Sulpiride:TI,AB,KY
#157 MESH DESCRIPTOR Tacrine
#158 Tacrine:TI,AB,KY
#159 MESH DESCRIPTOR Temazepam
#160 Temazepam:TI,AB,KY
#161 MESH DESCRIPTOR Thiopental
#162 Thiopental:TI,AB,KY
#163 MESH DESCRIPTOR Thioridazine
#164 Thioridazine:TI,AB,KY
#165 Trazadone:TI,AB,KY
#166 MESH DESCRIPTOR Triazolam
#167 Triazolam:TI,AB,KY
#168 MESH DESCRIPTOR Trifluoperazine
#169 Trifluoperazine:TI,AB,KY
#170 MESH DESCRIPTOR Triflupromazine
#171 Triflupromazine:TI,AB,KY




#176 MESH DESCRIPTOR Clopenthixol
#177 ((Zuclopenthixol or Clopenthixol)):TI,AB,KY
#178 MESH DESCRIPTOR Ondansetron
#179 ondansetron:TI,AB,KY
#180 quazepam:TI,AB,KY
#181 #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50
OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68
OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86
OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 OR #98 OR #99 OR #100 OR #101 OR #102 OR #103 OR
#104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #111 OR #112 OR #113 OR #114 OR #115 OR #116 OR #117 OR #118 OR #119
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OR #120 OR #121 OR #122 OR #123 OR #124 OR #125 OR #126 OR #127 OR #128 OR #129 OR #130 OR #131 OR #132 OR #133 OR #134 OR
#135 OR #136 OR #137 OR #138 OR #139 OR #140 OR #141 OR #142 OR #143 OR #144 OR #145 OR #146 OR #147 OR #148 OR #149 OR #150
OR #151 OR #152 OR #153 OR #154 OR #155 OR #156 OR #157 OR #158 OR #159 OR #160 OR #161 OR #162 OR #163 OR #164 OR #165 OR
#166 OR #167 OR #168 OR #169 OR #170 OR #171 OR #172 OR #173 OR #174 OR #175 OR #176 OR #177 OR #178 OR #179 OR #180
#182 #32 AND #181
MEDLINE (OVID)
1. Delirium/
2. (delirum or delirious).tw.
3. Psychomotor Agitation/
4. agitat*.tw.
5. (distress or distressed).tw.
6. restless*.tw.
7. ((disturbed or disordered or abnormal* or change*) adj2 (attention or cognition or cognitive or consciousness or perception)).tw.
8. "acute brain syndrome".tw.
9. "acute cerebral insuEiciency".tw.
10. "acute confusion".tw.
11. "acute confusional state".tw.
12. Cognitive Dysfunction/
13. (cognitive adj2 (dysfunction or decline)).tw.
14. (mental* adj2 deterioration).tw.
15. Consciousness Disorders/
16. (diminish* adj2 consciousness).tw.
17. Brain Diseases/
18. encephalopathy.tw.
19. (fail* adj2 cognit*).tw.
20. Neurocognitive Disorders/
21. organic mental disorder.tw.
22. "acute organic psychosyndrome*".tw.
23. "acute psycho-organic syndrome*".tw.
24. "exogenous psychosis".tw.
25. clouded state.tw.
26. (Cloud* adj2 conscious*).tw.
27. Brain Diseases, Metabolic/
28. (metabolic adj2 encephalopathy).tw.






















51. Cytidine Diphosphate Choline/
52. Citicoline.tw.
53. Clobazam.tw.
Drug therapy for delirium in terminally ill adults (Review)








































































Drug therapy for delirium in terminally ill adults (Review)







































































177. (Zuclopenthixol or Clopenthixol).tw.
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182. 32 and 181
183. randomized controlled trial.pt.







191. 183 or 184 or 185 or 186 or 187 or 188 or 189 or 190
192. exp animals/ not humans.sh.
193. 191 not 192
194. 182 and 193
Embase (OVID)
1. *Delirium/
2. (delirum or delirious).tw.
3. *restlessness/
4. agitat*.tw.
5. (distress or distressed).tw.
6. restless*.tw.
7. ((disturbed or disordered or abnormal* or change*) adj2 (attention or cognition or cognitive or consciousness or perception)).tw.
8. "acute brain syndrome".tw.
9. "acute cerebral insuEiciency".tw.
10. "acute confusion".tw.
11. "acute confusional state".tw.
12. *Cognitive Defect/
13. (cognitive adj2 (dysfunction or decline)).tw.
14. (mental* adj2 deterioration).tw.
15. *Consciousness Disorder/
16. (diminish* adj2 consciousness).tw.
17. *Brain Disease/
18. encephalopathy.tw.
19. (fail* adj2 cognit*).tw.
20. *"disorders of higher cerebral function"/
21. organic mental disorder.tw.
22. "acute organic psychosyndrome*".tw.
23. "acute psycho-organic syndrome*".tw.
24. "exogenous psychosis".tw.
25. clouded state.tw.
26. (Cloud* adj2 conscious*).tw.
27. metabolic encephalopathy/
28. (metabolic adj2 encephalopathy).tw.
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188. (doubl$ adj blind$).tw.






195. Randomized Controlled Trial/
196. Single Blind Procedure/
197. or/182-196
198. (animal/ or nonhuman/) not human/
199. 197 not 198
200. 32 and 181 and 199
PsycINFO (OVID)
1. Delirium/
2. (delirum or delirious).tw.
3. restlessness/
4. agitat*.tw.
5. (distress or distressed).tw.
6. restless*.tw.
7. ((disturbed or disordered or abnormal* or change*) adj2 (attention or cognition or cognitive or consciousness or perception)).tw.
8. "acute brain syndrome".tw.
9. "acute cerebral insuEiciency".tw.
10. "acute confusion".tw.
11. "acute confusional state".tw.
12. (cognitive adj2 (dysfunction or decline)).tw.
13. (mental* adj2 deterioration).tw.
14. Consciousness Disturbances/
15. (diminish* adj2 consciousness).tw.
16. ENCEPHALOPATHIES/
17. encephalopathy.tw.
18. (fail* adj2 cognit*).tw.
19. organic mental disorder.tw.
20. "acute organic psychosyndrome*".tw.
21. "acute psycho-organic syndrome*".tw.
22. "exogenous psychosis".tw.
23. clouded state.tw.
24. (Cloud* adj2 conscious*).tw.
25. metabolic encephalopathy/
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26. (metabolic adj2 encephalopathy).tw.
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160. (randomis* or randomiz*).tw.
161. (random$ adj3 (allocat$ or assign$)).tw.
162. ((clinic$ or control$) adj trial$).tw.
163. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.





169. exp program evaluation/
170. treatment eEectiveness evaluation/
171. ((eEectiveness or evaluat$) adj3 (stud$ or research$)).tw.
172. or/159-171
173. or/1-29
174. 158 and 172 and 173
175. limit 174 to human
CINAHL
S178 S168 and S177
S177 S169 or S170 or S171 or S172 or S173 or S174 or S175 or S176
S176 (allocat* random*)




S171 (MH "Random Assignment")
S170 (Randomi?ed control* trial*)
S169 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or (singl*
mask* )
S168 S31 AND S167
S167 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR
S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78 OR
S79 OR S80 OR S81 OR S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88 OR S89 OR S90 OR
S91 OR S92 OR S93 OR S94 OR S95 OR S96 OR S97 OR S98 OR S99 OR S100 OR S101 OR S102
OR S103 OR S104 OR S105 OR S106 OR S107 OR S108 OR S109 OR S110 OR S111 OR S112 OR
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S113 OR S114 OR S115 OR S116 OR S117 OR S118 OR S119 OR S120 OR S121 OR S122 OR
S123 OR S124 OR S125 OR S126 OR S127 OR S128 OR S129 OR S130 OR S131 OR S132 OR
S133 OR S134 OR S135 OR S136 OR S137 OR S138 OR S139 OR S140 OR S141 OR S142 OR
S143 OR S144 OR S145 OR S146 OR S147 OR S148 OR S149 OR S150 OR S151 OR S152 OR
S153 OR S154 OR S155 OR S156 OR S157 OR S158 OR S159 OR S160 OR S161 OR S162 OR








S159 (MH "Valproic Acid")
S158 Triflupromazine
S157 Trifluoperazine
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S103 (MH "Nitrous Oxide")
S102 Nitrazepam
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S31 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR
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S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR
S25 OR S26 OR S27 OR S28 OR S29 OR S30
S30 toxic confusion
S29 toxic psychosis
S28 (disturbance N2 brain function)
S27 (metabolic N2 encephalopathy)
S26 (MH "Brain Diseases, Metabolic")
S25 (Cloud* N2 conscious*)
S24 clouded state
S23 "exogenous psychosis"
S22 "acute psycho-organic syndrome*"
S21 "acute organic psychosyndrome*"
S20 organic mental disorder
S19 (fail* N2 cognit*)
S18 encephalopathy
S17 (MH "Brain Diseases")
S16 (diminish* N2 consciousness)
S15 (MH "Consciousness Disorders")
S14 (mental* N2 deterioration)
S13 (cognitive N2 (dysfunction or decline))
S12 "acute confusional state"
S11 "acute confusion"
S10 "acute cerebral insuEiciency"
S9 "acute cerebral insuEiciency"
S8 "acute brain syndrome"
S7 ((disturbed or disordered or abnormal* or change*) N2 (attention or cognition or cognitive or consciousness or perception))
S6 restless*
S5 (distress or distressed)
S4 agitat*
S3 (MH "Psychomotor Agitation")
S2 (delirum or delirious)
S1 (MH "Delirium")
W H A T ' S   N E W
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Date Event Description
22 January 2020 Review declared as stable See Published notes.
 
H I S T O R Y
Protocol first published: Issue 2, 2004
Review first published: Issue 2, 2004
 
Date Event Description
12 September 2019 New citation required and conclusions
have changed
We broadened the search criteria and removed the population
search terms "terminal or advanced disease or palliative" to re-
duce the risk of missing potentially relevant studies. Three new
studies were identified, bringing the total included to four. In
total, 399 terminally ill adults with delirium were randomised.
A GRADE assessment was added. Since the last review, there is
low-quality evidence that haloperidol or risperidone may worsen
delirium symptoms compared with placebo in participants with
delirium of mild to moderate severity.
10 July 2019 New search has been performed This review has been updated to include results of a new search
performed on 8 July 2019
20 September 2012 New citation required but conclusions
have not changed
Assessed as up to date.
1 June 2012 New search has been performed New searches and assessed as up to date.
1 June 2011 New search has been performed New searches were run. We also updated all sections.
12 August 2009 Amended Contact details updated.
27 October 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
In the 2019 update, all authors updated the search strategy. AMF and BC independently screened the citation searches. AMF, LJ, BL, ELS,
PS and BL assessed the eligibility of full-text papers retrieved following screening. AMF and BC draNed the review. BL provided advice and
support for statistical analysis and commentary on the findings. All authors commented on the draN review and agreed the final document.
AMF and BC will be responsible for further updates.




ELS: none known. ELS is a consultant in Liaison Psychiatry and manages people with delirium in an acute hospital.
PS: none known. PS is a consultant in palliative medicine and manages patients with terminal illness.
AT: none known. AT is a specialist palliative care physician and manages patients with terminal illness.
BC: none known.
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S O U R C E S   O F   S U P P O R T
Internal sources
• Marie Curie, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Changes made for the 2012 update
For the 2012 update we ran a new search and updated the Background, Methods, Results and Discussion sections to comply with current
Cochrane requirements.
Changes made for the 2019 update
We changed the title from "Drug therapy for delirium in terminally ill adult patients" to "Drug therapy for delirium in terminally ill adults".
We updated the background to reflect new research findings.
We amended the search strategy. Palliative care is an approach that improves the quality of life of patients’ families facing the problems
associated with life-threatening illness (WHO 2018), thus evidence relevant to a person experiencing any life-threatening illness is
relevant, irrespective of whether they are explicitly recognised as having a terminal or advanced illness or are in receipt of palliative
care. Consequently, we removed the population search terms in order to include a wider range of papers, and not just those papers that
specifically refer to advanced disease, palliative care and terminal illness. We also amended the individual treatment terms to include all
generic drug names potentially relevant to delirium management, and we replaced brand names with generic names where appropriate.
We removed the search terms relating to drug class names as all relevant drugs should be included in the individual treatment search terms.
We updated the Methods section to reflect current Cochrane guidelines, in particular in risk of bias and quality (GRADE) assessment, and
included 'Summary of findings' tables. We further defined our outcomes of interest, with regards to measurement time points. We included
agitation as a primary outcome as it frequently occurs with delirium, is highly distressing to patients, caregivers and professionals, and
poses a safety risk to those involved. We now include extrapyramidal eEects as a type of adverse event.
We updated our discussion to incorporate the results from three new studies.
N O T E S
This review has been stabilised following discussion with the authors and editors. We will reassess the review for updating in 2025. We
will update the review sooner than this if new evidence likely to change the conclusions is published, or if standards change substantially
which necessitate major revisions.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents  [therapeutic use];  Chlorpromazine  [therapeutic use];  Delirium  [*drug therapy]  [etiology];  Haloperidol
 [therapeutic use];  Lorazepam  [therapeutic use];  Randomized Controlled Trials as Topic;  Terminally Ill  [*psychology]
MeSH check words
Adult; Humans
Drug therapy for delirium in terminally ill adults (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
83
